







 
 
  



<HTML>
<HEAD>
<TITLE>
	
	Agonist Regulation of D2 Dopamine Receptor/G Protein Interaction. EVIDENCE FOR AGONIST SELECTION OF G PROTEIN SUBTYPE -- Cordeaux et al. 276 (31): 28667 -- Journal of Biological Chemistry</TITLE>


	<SCRIPT LANGUAGE="JavaScript">
	<!--
	function startTarget(windowname,wid,hei) {
	
	var dotpos = windowname.indexOf(".");
	if (dotpos > -1)
	{
	var tempwn = windowname.substring(0,dotpos) +
		windowname.substring(dotpos + 1, windowname.length);
	windowname = tempwn;
	}
	var sizestring = 'width=' + wid + ',height=' + hei;
	window.open('',windowname,'scrollbars,resizable,' + sizestring + '\'');
	}
	// -->
	</SCRIPT>




	<!-- has inhead tag -->
	
		 
	 
	<script language="JavaScript">
	<!--
	if ( top != self )
	{
		top.location.href = unescape(window.location.pathname);
	}
	//-->
	</script>
	
		
	
		<style type="text/css"><!--
table.content_box_outer_table {
	padding-left:10px;
	padding-bottom:5px;
	padding-top:0px;
	padding-right:0px;
	}

table.content_box_outer_table_in_sidebar_frame {
	padding-left:10px;
	padding-bottom:0px;
	padding-top:10px;
	padding-right:10px;
	}

table.content_box_inner_table {
	background-color:#f0f0f0;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:5px;
	}

table.content_box_pdfinframes {
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:4px;
	}

td.content_box_title_highlight {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#006699;
	font-size:120%;
	font-weight:bold;
	text-align:center;
	padding:1px;
	vertical-align:middle;
	}

td.content_box_title {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#828282;
	font-size:120%;
	font-weight:bold;
	padding:1px;
	text-align:center;
	vertical-align:middle;
	}

td.content_box_space_between_sections {
	padding-top:2px;
	}

td.content_box_arrow {
	text-align:right;
	padding-left:5px;
	padding-right:0px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_item {
	text-align:left;
	vertical-align:top;
	padding-left:3px;
	padding-right:5px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_pdfinframes_citation_cell {
	background-color:#ffffff;
	border:1px #000000 solid;
	padding:3px;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	text-align:left;
	}


font.openaccess {
	font-weight:bold;
	padding-left:3px;
	padding-right:3px;
	background-color:#ffffff;
	}
font.openaccess_open {
	color:#000000;
	}
font.openaccess_access {
	color:#cc0000;
	}
font.openaccess_oa {
	}
.content_box_openaccess_title {
	text-align:center;
	white-space:nowrap;
	background-color:#BABABA;
	}

--></style>

		
	<script language="javascript">
		<!-- 
	function popwin(url,wid,hei,fromtop,fromleft) {
		var winPref = "channelmode=no,toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=auto,resizable=no,width=" + wid + ",height=" + hei + ",top=" + fromtop + ",left=" + fromleft;
		window.open(url, "popwin", winPref);
	}
	// -->
	</script>

<meta name="robots" content="nofollow">
<META NAME="ROBOTS" CONTENT="NOARCHIVE"> 

</HEAD>
<BODY BGCOLOR="#FFFFFF" 
	
		
			
		
	>



<A NAME="top"><!-- null --></A>

	
	<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0">
	<TR>
		<TD VALIGN="BOTTOM" NOWRAP>
			<A TARGET="_top" STYLE="text-decoration: none" HREF="/"><IMG BORDER="0" WIDTH="220" HEIGHT="44" ALT="JBC" SRC="/icons/banner/title.gif"></A>
			<A HREF="/cgi/adclick/?ad=4153&adclick=true&url=http://www.asbmb.org/ASBMB/site.nsf/web/1311115994955D2C85256E8D0070FDC3%3FOpenDocument"><IMG SRC="/adsystem/graphics/jbc/1098385511.gif?ad=4153&adview=true" ALT="Genomes and Proteomes Meeting" BORDER="1" WIDTH="220" HEIGHT="40"></A><BR><IMG ALT="" WIDTH="1" HEIGHT="3" SRC="/icons/spacer.gif"><BR>
			
	<TABLE CELLPADDING="2" CELLSPACING="2" WIDTH="450">
	<TR>
		<TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">HOME</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/help/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">HELP</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/cgi/feedback"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">FEEDBACK</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/subscriptions/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">SUBSCRIPTIONS</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/contents-by-date.0.shtml"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">ARCHIVE</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/search.dtl"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">SEARCH</FONT></A></TD>
	    


<TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/content/vol276/issue31/index.shtml"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">TABLE OF CONTENTS</FONT></A></TD>




	</TR>
	</TABLE>
	</TD>
		<TD><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
		<TD VALIGN="BOTTOM">
	
	<TABLE CELLPADDING="0" CELLSPACING="1" BORDER="0" BGCOLOR="#000000"><TR>
	<FORM METHOD="GET" NAME="search" ACTION="/cgi/search"><INPUT TYPE="hidden" NAME="andorexactfulltext" VALUE="and"><INPUT TYPE="hidden" NAME="resourcetype" VALUE="1"><INPUT TYPE="hidden" NAME="disp_type" VALUE=""><INPUT TYPE="hidden" NAME="sortspec" VALUE="relevance"><TD ALIGN="CENTER" VALIGN="MIDDLE"> 
		<TABLE CELLPADDING="1" CELLSPACING="0" BORDER="0" BGCOLOR="#DBDBDB"> 
		<TR>
			<TD BGCOLOR="#006699"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
			<TD VALIGN="MIDDLE"  BGCOLOR="#006699" NOWRAP><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#FFFFFF"><EM>QUICK</EM> SEARCH:&nbsp;</FONT></STRONG></TD>
			<TD ALIGN="RIGHT" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A STYLE="text-decoration:none;color:#FFFFFF" HREF="/search.dtl"><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">&nbsp;[advanced]</FONT></A></TD>
			<TD BGCOLOR="#006699"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
		</TR><TR>
			<TD BGCOLOR="#DBDBDB"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
			<TD BGCOLOR="#DBDBDB" COLSPAN="2">
			<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0"> 
			<TR>
				<TD ALIGN="CENTER" VALIGN="BOTTOM"><INPUT TYPE="submit" STYLE="text-decoration:none;font-family:verdana,arial,helvetica;font-size:10px;font-weight:bold;color:#000000;background:#FFFFFF;" VALUE="Go"></TD>
				<TH ALIGN="LEFT" COLSPAN="2"><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Author:<BR></FONT>
					<INPUT TYPE="text" NAME="author1" SIZE="9" MAXLENGTH="80" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TH>
				<TH ALIGN="LEFT" COLSPAN="3"><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Keyword(s):<BR></FONT>
					<INPUT TYPE="text" NAME="fulltext" SIZE="16" MAXLENGTH="80" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TH>
			</TR><TR>
				<TH><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Year:&nbsp;</FONT></TH>
				<TD><INPUT TYPE="text" NAME="pubdate_year" SIZE="4" MAXLENGTH="4" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TD>
				<TH ALIGN="RIGHT"><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Vol:&nbsp;</FONT></TH>
				<TD><INPUT TYPE="text" NAME="volume" SIZE="4" MAXLENGTH="10" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TD>
				<TH><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Page:&nbsp;</FONT></TH>
				<TD><INPUT TYPE="text" NAME="firstpage" SIZE="4" MAXLENGTH="10" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TD>
			</TR> 
			</TABLE> </TD>
			<TD BGCOLOR="#DBDBDB"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
		</TR>
		</TABLE></TD></FORM></TR></TABLE> 
	 
	</TD>
	</TR><TR>
		<TD COLSPAN="3"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"><BR>







	
	

	





	
	
	
	 

	


	
	




				<FONT SIZE="-2" FACE="verdana,arial,helvetica">
	<NOBR><STRONG>Institution: Cornell University Medical College</STRONG></NOBR>
	<NOBR><A TARGET="_top" HREF="/cgi/login?uri=%2Fcgi%2Fcontent%2Ffull%2F276%2F31%2F28667">Sign In as Member/Non-Member</A></NOBR>
	
		
		
	
	
	</FONT>
	
 <!-- showauthstring -->
	<!-- INST -->
	<!-- INDV -->
        <!-- SPONSORED -->
	<!-- USER.PFA -->
	<!-- USER.PFABSAIC -->
	<!-- NOT GUEST -->
	

	


<HR ALIGN="LEFT" SIZE="1" COLOR="#000000" NOSHADE></TD>
	</TR>
	</TABLE>



















	






	
		
		
	 
 




		<FONT COLOR="#A70716"></FONT>
	
	<FONT SIZE=-1>Originally published In Press as  <A HREF="/cgi/content/abstract/M008644200v1">doi:10.1074/jbc.M008644200</A> on May 21, 2001</FONT>


	
		
		<P><FONT SIZE=-1>J. Biol. Chem., Vol. 276, Issue 31, 28667-28675, August 3, 2001</FONT><BR>
		
	

 

 
	  
		
	
		<table class="content_box_outer_table"
		 
			
				
					align="right"
				
			
		>
			<tr>
			<td>
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				
				<strong><a href="/cgi/content/abstract/276/31/28667">
				Abstract</a></strong>
				 					<img alt="" width="32" height="7" border="0" src="/icons/shared/toc/free.gif">
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	

	
	
	

	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		
		
		
			
				
				
					<a href="/cgi/reprint/276/31/28667">
		<strong>Full Text</strong> (PDF)</a>
				
			
		
		</strong>
		</td></tr>
	
	

	
	
	

	
	
	

	
	





	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			

			
	
	

	
		
	









	
		
	
		
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item"><strong>
			All Versions of this Article:<br>
		
			
					276/31/28667
				
		&nbsp;&nbsp;&nbsp;<font color="#006699"><em>most recent</em></font><br>
	

	
		
		
			<a href="/cgi/content/short/M008644200v1">
					M008644200v1</a>
			
		</strong></td></tr>
	

	





	

	 

	

	
	
		  
    

	







		
	
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=jbc;276/31/28667&return_type=article&return_url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F31%2F28667">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=correction&addAlert=correction&saveAlert=no&correction_criteria_value=276/31/28667&return_type=article&return_url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F31%2F28667">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		










			
		
			
			
			
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
					<strong><a href="/cgi/citemap?id=jbc;276/31/28667">
					Citation Map</a></strong>
				</td></tr>
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/mailafriend?url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F31%2F28667&title=Agonist+Regulation+of+D2+Dopamine+Receptor%2FG+Protein+Interaction.+EVIDENCE+FOR+AGONIST+SELECTION+OF+G+PROTEIN+SUBTYPE">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

		
		



			
			
			
		
	

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		<a href="/cgi/search?qbe=jbc;M008644200&journalcode=jbc&minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=11369753&link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
	

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="/cgi/citmgr?gca=jbc;276/31/28667">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	


	
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="#otherarticles">
				Cited by other online articles</a></strong>
			</td></tr>
		
	
		
	

	

		


	
	
	
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><A HREF="/misc/ASBMB_Copyright_Request.pdf">Copyright Permissions</a></strong>
			</td></tr>
		

	

	






	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=11369753&link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Cordeaux+Y&link_type=AUTHORSEARCH">
							Articles by Cordeaux, Y.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Strange+PG&link_type=AUTHORSEARCH">
							Articles by Strange, P. G.</a></strong>
						</td></tr>
				
			
		

		
	






	






	
		

	

		
			
		











	




	</td></tr></table>
</td></tr></table> 

	











 





	
	
	
	
	
	
	
	
	
		<vardef id="TEXT">

<!--

   Pages created by the Electronic Press Engine from

		Atypon Systems, Inc.

   Visit http://www.atypon.com/

-->





<H2>
<FONT COLOR=A70716 SIZE=-1>

</FONT>

    Agonist Regulation of D<SUB>2</SUB> Dopamine Receptor/G Protein
Interaction
    <BR>

<font size=-1><BR>EVIDENCE FOR AGONIST SELECTION OF G PROTEIN SUBTYPE<A HREF="#FN150"><SUP>*</SUP></A></font>
</H2>



<STRONG>
<NOWRAP>
Yolande 
Cordeaux<A HREF="#FN152"><SUP><IMG SRC="/math/12pt/normal/link/Dagger.gif" ALIGN=BOTTOM ALT="Dagger" BORDER=0></SUP></A>,<WBR>
Sarah A. 
Nickolls,<WBR>
Lori A. 
Flood<SUP>&#167;</SUP>,<WBR>
Stephen G. 
Graber<SUP>&#167;</SUP>, and<WBR>
Philip G. 
Strange<A HREF="#FN154"><SUP>&#182;</SUP></A>
</NOWRAP>
</STRONG>
<P>
From the School of Animal and Microbial Sciences, University of
Reading, Whiteknights, Reading, Berkshire RG6 6AJ, United Kingdom and
the <SUP>&#167;</SUP>&nbsp;Department of Pharmacology and Toxicology, West
Virginia University, Morgantown, West Virginia 26506-9223
<P>
Received for publication, September 21,&nbsp;2000, and in revised form, April 26,&nbsp;2001
<P>






    
	
	    
	
	    
		
    
	
	    
	
    
	
	    
	
    
    
	
	    
	
    







<a name = "Abstract"><!-- comment for mosaic --></a>



<A NAME="Abstract"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;ABSTRACT</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>ABSTRACT</FONT>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">INTRODUCTION</A>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">RESULTS</A>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>

<P>The D<SUB>2</SUB> dopamine receptor
has been expressed in Sf21 insect cells together with the G
proteins G<SUB>o</SUB> and G<SUB>i2</SUB>, using the
baculovirus<SUP> </SUP>system. Expression levels of receptor and G protein (<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">,
<IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta ">, and<SUP> </SUP><IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">&nbsp;subunits) in the two preparations were similar as shown by
binding<SUP> </SUP>of [<SUP>3</SUP>H]spiperone and quantitative Western blot,
respectively. For several<SUP> </SUP>agonists, binding data were fitted best by a
two-binding site<SUP> </SUP>model in either preparation, showing interaction of
expressed<SUP> </SUP>receptor and G protein. For some agonists, binding to the
higher<SUP> </SUP>affinity site was of higher affinity in
D<SUB>2</SUB>/G<SUB>o</SUB> than in the
D<SUB>2</SUB>/G<SUB>i2</SUB><SUP> </SUP>preparation. Some agonists exhibited
binding data that were best<SUP> </SUP>fitted by a two-binding site model in
D<SUB>2</SUB>/G<SUB>o</SUB> and a one-binding<SUP> </SUP>site model in
D<SUB>2</SUB>/G<SUB>i2</SUB>. Therefore, receptor/G protein
interaction<SUP> </SUP>seemed to be stronger in the D<SUB>2</SUB>/G<SUB>o</SUB>
preparation. Agonist stimulation<SUP> </SUP>of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S
(guanosine 5'-3-<I>O</I>-(thio)triphosphate) binding in the two<SUP> </SUP>preparations also gave evidence for higher affinity
D<SUB>2</SUB>/G<SUB>o</SUB> interaction.<SUP> </SUP>In the
D<SUB>2</SUB>/G<SUB>o</SUB> preparation, agonist stimulation of
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding occurred at higher potency for
several agonists,<SUP> </SUP>and a higher stimulation (relative to dopamine) was
achieved in<SUP> </SUP>D<SUB>2</SUB>/G<SUB>o</SUB> compared with
D<SUB>2</SUB>/G<SUB>i2</SUB>. Some agonists were able to stimulate<SUP> </SUP>[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding in the D<SUB>2</SUB>/G<SUB>o</SUB>
preparation but not in D<SUB>2</SUB>/G<SUB>i2</SUB>. The<SUP> </SUP>extent of
D<SUB>2</SUB> receptor selectivity for G<SUB>o</SUB> over
G<SUB>i2</SUB> is therefore<SUP> </SUP>dependent on the agonist used, and thus
agonists may stabilize<SUP> </SUP>different conformations of the receptor with
different abilities<SUP> </SUP>to couple to and activate G<SUP> </SUP>proteins.
<BR><BR CLEAR=ALL>




<TXT>
<A NAME="SEC0"><!-- comment for mosaic --></A>

    
    

    
    

    
    
	
	
	
<A NAME="Introduction"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;INTRODUCTION</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>INTRODUCTION</FONT>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">RESULTS</A>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>

    

<P>There is considerable interest in understanding the action
mechanisms of agonists at receptors (<A HREF="#B1">1-3</A>). Agonists must bind<SUP> </SUP>to
receptors, and this may be characterized in terms of an affinity<SUP> </SUP>of
agonist binding. Agonists must also activate the receptor and<SUP> </SUP>associated signaling systems, and this property is often referred<SUP> </SUP>to as
efficacy. Efficacy is exhibited in terms of the maximal<SUP> </SUP>effect induced
by the agonist and also in the EC<SUB>50</SUB> of the agonist<SUP> </SUP>in
activating the signaling system, which is often lower than<SUP> </SUP>the
concentration of agonist which achieves half-maximal occupancy<SUP> </SUP>of the<SUP> </SUP>receptor.
</P>
<P>For G protein-coupled receptors, an influential model of agonist action
is the ternary complex model and its recent extensions<SUP> </SUP>(<A HREF="#B4">4-6</A>). In this
model the receptor exists in an inactive ground<SUP> </SUP>state, which may
isomerize to a partially activated state
(R*</A>)<SUP>1</SUP> that is able to couple
more efficiently to the G protein to form<SUP> </SUP>the coupled active species
(R*G</A>). The formation of R*G</A> may occur<SUP> </SUP>spontaneously, but in the
presence of an agonist both R*</A> and R*G</A><SUP> </SUP>are stabilized, and the ternary
complex (AR*G</A>) is formed. Guanine<SUP> </SUP>nucleotide exchange (GDP/GTP) occurs
in both the binary complex<SUP> </SUP>(R*G</A>) and the ternary complex (AR*G</A>). The
binary and ternary complexes<SUP> </SUP>dissociate releasing <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">GTP and <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">
subunits of the G protein which<SUP> </SUP>can alter effector activity. The
agonist may also influence ternary<SUP> </SUP>complex breakdown (<A HREF="#B7">7</A>, <A HREF="#B8">8</A>) so that
there are several places<SUP> </SUP>at which agonism is<SUP> </SUP>determined.
</P>
<P>There is, however, evidence that some receptors may
interact with more than one G protein so that influences on different<SUP> </SUP>signaling pathways can occur. If a receptor can interact with<SUP> </SUP>more than
one G protein this may influence the potency of agonist<SUP> </SUP>action and the
pattern of agonist effects, <I>i.e.</I> the pharmacological<SUP> </SUP>profile
of the response observed through the different G proteins.<SUP> </SUP>For the
5HT1A serotonin receptor, it was shown that the receptor<SUP> </SUP>interacts
preferentially with G<SUB>i</SUB>/G<SUB>o</SUB>/G<SUB>z</SUB>
subtypes of G protein (<A HREF="#B9">9</A>)<SUP> </SUP>and that the nature of the G protein subtype
influenced the agonist<SUP> </SUP>selectivity of the response (<A HREF="#B10">10</A>). This question
was addressed<SUP> </SUP>more explicitly for the <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>2</SUB>-adrenergic
receptor (<A HREF="#B11">11</A>). Expression<SUP> </SUP>of G<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>o</SUB>, together with the
endogenous G proteins of NIH 3T3 cells,<SUP> </SUP>altered the agonist selectivity
of the receptor; the partial agonists,<SUP> </SUP>oxymetazoline and clonidine,
exhibited increased efficacy. The<SUP> </SUP>possibility that the pharmacological
profile of the response depends<SUP> </SUP>on the nature of the G protein has been
termed "agonist trafficking"<SUP> </SUP>(<A HREF="#B12">12</A>).
</P>
<P>The D<SUB>2</SUB> dopamine receptor has been shown to interact with
different G proteins to influence different signaling events (<A HREF="#B13">13</A>,<SUP> </SUP><A HREF="#B14">14</A>).
In one study, interaction with G<SUB>o</SUB> has been shown to lead<SUP> </SUP>to
inhibition of calcium channels, whereas interaction with G<SUB>i</SUB><SUP> </SUP>subtypes has been shown to lead to inhibition of adenylyl cyclase<SUP> </SUP>(<A HREF="#B15">15</A>).
Also, the two splice variants of the D<SUB>2</SUB> receptor
(D<SUB>2short</SUB><SUP> </SUP>and D<SUB>2long</SUB>) have been reported to
interact with different G proteins<SUP> </SUP>(<A HREF="#B13">13</A>), although a clear definition of
the selectivity pattern<SUP> </SUP>has not emerged as yet. Furthermore, the
relative efficacies of<SUP> </SUP>quinpirole and (+)-3-PPP are reversed
when tested on the D<SUB>2</SUB> receptor<SUP> </SUP>in the striatum and the
pituitary gland (<A HREF="#B16">16</A>), suggesting agonist<SUP> </SUP>trafficking, possibly via
different G<SUP> </SUP>proteins.
</P>
<P>To investigate these phenomena we have expressed the D<SUB>2</SUB>
dopamine receptor together with the G proteins G<SUB>o</SUB> and
G<SUB>i2</SUB> in insect<SUP> </SUP>cells, using the baculovirus system (<A HREF="#B17">17</A>).
This system provides<SUP> </SUP>a powerful tool for the reconstitution of
receptor/G protein interactions.<SUP> </SUP>Insect cells do not contain endogenous
dopamine receptors, and<SUP> </SUP>interaction between recombinant receptors and
the endogenous G<SUP> </SUP>proteins of the cells is<SUP> </SUP>minimal.
<BR><BR CLEAR=ALL>



<A NAME="SEC1"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;EXPERIMENTAL PROCEDURES</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">INTRODUCTION</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>EXPERIMENTAL PROCEDURES</FONT>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">RESULTS</A>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>


    


<P ALIGN=CENTER><B>Materials</B>
</P>


    
    <P>[<I>phenyl</I>-4-<SUP>3</SUP>H]Spiperone (25Ci/mmol) was
from <a href="/cgi/inline?Amersham%20Pharmacia%20Biotech">Amersham Pharmacia Biotech</a>, and [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S (1,250&nbsp;Ci/mmol) was from PerkinElmer Life Sciences. Antibodies<SUP> </SUP>specific for
different G protein subunits were from Chemicon and<SUP> </SUP>Santa Cruz as
indicated. Other reagents were obtained as indicated<SUP> </SUP>or were of the
highest purity available from commercial<SUP> </SUP>suppliers.
    
    


    
    </P>

    


<P ALIGN=CENTER><B>Methods</B>
</P>


    



    


<P><I>Cell Culture--</I>

Sf21 cells were grown either in
monolayers or in suspension, using shaker flasks (25-100-ml cultures)
agitated at 116&nbsp;rpm.<SUP> </SUP>Cells were cultured at 26&nbsp;&#176;C in TC100 medium
supplemented with<SUP> </SUP>8% fetal calf serum and 0.1% Pluronic F-68 (Life
Technologies,<SUP> </SUP>Inc.). CHO</A> cells expressing the long form of the rat
D<SUB>2</SUB> dopamine<SUP> </SUP>receptor (<A HREF="#B18">18</A>, <A HREF="#B19">19</A>) were grown in RPMI medium
containing 5%<SUP> </SUP>fetal calf serum, 2&nbsp;m<font size=-1>M</font>
<font size=-1>L</font>-glutamine, and 2&nbsp;m<font size=-1>M</font> active<SUP> </SUP>Geneticin.



    

    


<P><I>Construction and Isolation of Recombinant Baculovirus and
Expression of the D<SUB>2</SUB> Dopamine Receptor and G Protein
Subunits in Sf21 Cells--</I>

The baculovirus transfer vector,
containing the cDNA for the FLAG-tagged D<SUB>2long</SUB> dopamine
receptor, was constructed from three<SUP> </SUP>DNA fragments (<A HREF="#B20">20</A>). The first
fragment consisted of the generic<SUP> </SUP>baculovirus transfer nonfusion
vector, pVL1392 (PharMingen), digested<SUP> </SUP>with <I>Pst</I>I and
<I>Bam</I>HI. The second fragment was generated by polymerase<SUP> </SUP>chain
reaction and comprised at its 5'-end, a <I>Pst</I>I
restriction<SUP> </SUP>site, to facilitate ligation to the vector, an ATG start
codon,<SUP> </SUP>immediately followed by DNA encoding the FLAG epitope and the<SUP> </SUP>first 116&nbsp;amino acids of the rat D<SUB>2long</SUB> receptor sequence,
and<SUP> </SUP>at its 3'-end, an <I>Alw</I>44I restriction site to allow
ligation to<SUP> </SUP>the final cDNA fragment. The final fragment was a
1.0-kilobase<SUP> </SUP>cDNA fragment, coding for the remaining amino acids of
the dopamine<SUP> </SUP>receptor, and was excised from an existing baculovirus
transfer<SUP> </SUP>vector containing receptor cDNA (pVL1392D2), using
<I>Alw</I>44I and<SUP> </SUP><I>Bam</I>HI. The sequence of the DNA
corresponding to the polymerase<SUP> </SUP>chain reaction fragment and the three
ligation sites was confirmed<SUP> </SUP>by dideoxy DNA sequencing using the
Sequenase version 2.0&nbsp;DNA<SUP> </SUP>sequencing kit (United States Biochemical).
Transfer of the FLAG-D<SUB>2long</SUB><SUP> </SUP>cDNA into the
<I>Autographa californica</I> nuclear polyhedrosis virus<SUP> </SUP>genome in
the form of BaculoGold (PharMingen) was achieved by<SUP> </SUP>cotransfecting
Sf21 cells with plasmid DNA and BaculoGold in the<SUP> </SUP>presence of
Lipofectin (Life Technologies, Inc.). Recombinant<SUP> </SUP>baculovirus was
purified by a single round of plaque purification<SUP> </SUP>(<A HREF="#B17">17</A>) and stocks
amplified (100-ml cultures, multiplicity of<SUP> </SUP>infection&nbsp;=&nbsp;0.1). For
expression, cells were infected at a cell<SUP> </SUP>density of 1&nbsp;&#215;&nbsp;10<SUP>6</SUP> cells/ml with recombinant baculovirus at a multiplicity
of infection<SUP> </SUP>of 10.&nbsp;Baculoviruses containing G protein sequences were
constructed<SUP> </SUP>as described (<A HREF="#B21">21</A>).



    

    


<P><I>Preparation of Washed Cell Homogenates--</I>

All operations were
carried out at 0-4&nbsp;&#176;C. Sf21 cells were harvested 48&nbsp;h
after infection by centrifugation at 3,000&nbsp;&#215;&nbsp;<I>g</I> for<SUP> </SUP>10&nbsp;min and resuspended at ~5&nbsp;&#215;&nbsp;10<SUP>7</SUP> cells/ml in 20&nbsp;m<font size=-1>M</font> HEPES, pH 7.4,&nbsp;6&nbsp;m<font size=-1>M</font> MgCl<SUB>2</SUB>, 1&nbsp;m<font size=-1>M</font> EDTA, 1&nbsp;m<font size=-1>M</font><SUP> </SUP>EGTA, and protease inhibitors
(Boehringer COMPLETE <SUP>TM</SUP>). Sf21 cells<SUP> </SUP>were homogenized with 50&nbsp;strokes of a Dounce homogenizer and centrifuged<SUP> </SUP>at 3,000&nbsp;&#215;&nbsp;<I>g</I> for 10&nbsp;min. The supernatant was collected and centrifuged<SUP> </SUP>at 48,000&nbsp;&#215;&nbsp;<I>g</I> for 60&nbsp;min, and the pellet was
resuspended in 20<SUP>&nbsp;</SUP>m<font size=-1>M</font> HEPES, pH 7.4,&nbsp;10&nbsp;m<font size=-1>M</font> EDTA,
1&nbsp;m<font size=-1>M</font> EGTA, and protease inhibitors<SUP> </SUP>(Boehringer COMPLETE
<SUP>TM</SUP>). The resulting washed membrane homogenates<SUP> </SUP>were stored at
<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">80&nbsp;&#176;C until used for Western blot analysis or<SUP> </SUP>ligand binding<SUP> </SUP>assays.
<P>
Membrane preparations from CHO</A> cells expressing D<SUB>2</SUB> dopamine
receptors were made as described by Castro and Strange (<A HREF="#B18">18</A>,<SUP> </SUP><A HREF="#B19">19</A>).



    

    


<P><I>Protein Determination--</I>

Protein was determined using the
Lowry method (<A HREF="#B22">22</A>), with bovine serum albumin as the<SUP> </SUP>standard.



    

    


<P><I>Ligand Binding Assays--</I>

Binding to washed membrane
homogenates (15-50 &#181;g of protein) was assayed in triplicate using
[<I>phenyl</I>-4-<SUP>3</SUP>H]spiperone (25Ci/mmol;
0.1-5 n<font size=-1>M</font> for saturation analyses and 1<SUP>&nbsp;</SUP>n<font size=-1>M</font> for
competition assays). Except where indicated, assays were<SUP> </SUP>performed in a
final volume of 1&nbsp;ml of assay buffer: 20&nbsp;m<font size=-1>M</font> HEPES,<SUP> </SUP>1&nbsp;m<font size=-1>M</font> EDTA, 1&nbsp;m<font size=-1>M</font> EGTA, 6&nbsp;m<font size=-1>M</font>
MgCl<SUB>2</SUB>, pH 7.4.&nbsp;In agonist binding assays,<SUP> </SUP>100&nbsp;&#181;<font size=-1>M</font> dithiothreitol was added as an antioxidant. For
substituted<SUP> </SUP>benzamide antagonists, the standard assay buffer was
supplemented<SUP> </SUP>with 100&nbsp;m<font size=-1>M</font> NaCl or <I>N</I>-methyl
<font size=-1>D</font>-glucamine (NMDG</A>) as indicated.<SUP> </SUP>Binding was measured in
the presence of 3&nbsp;&#181;<font size=-1>M</font> (<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-butaclamol and<SUP> </SUP>(+)-butaclamol
to define total and nonspecific binding, respectively,<SUP> </SUP>over a period of
180&nbsp;min at 25&nbsp;&#176;C. Bound and free radioligands<SUP> </SUP>were separated by
rapid filtration through GF/B filters on a Brandel<SUP> </SUP>cell harvester with
four washes of 4&nbsp;ml of phosphate-buffered<SUP> </SUP>saline (0.14&nbsp;<font size=-1>M</font>
NaCl, 3&nbsp;m<font size=-1>M</font> KCl, 1.5&nbsp;m<font size=-1>M</font>
KH<SUB>2</SUB>PO<SUB>4</SUB>, and 5&nbsp;m<font size=-1>M</font>
Na<SUB>2</SUB>HPO<SUB>4</SUB>,<SUP> </SUP>pH 7.4). Bound radioactivity was
determined by liquid scintillation<SUP> </SUP>counting. Ligand binding data were
analyzed by nonlinear least<SUP> </SUP>squares regression using the computer
program GraphPad Prism (GraphPad<SUP> </SUP>Software Inc.).
<P>
In some saturation assays a total assay volume of 10&nbsp;ml was employed.
The protein amount was the same as in the 1-ml assays<SUP> </SUP>so that the
protein concentration was 10-fold lower. The concentrations<SUP> </SUP>of other
substances were the same as in the 1-ml assays, but the<SUP> </SUP>time of
incubation was 7<SUP>&nbsp;</SUP>h.



    

    


<P><I>[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S Binding Assays--</I>

In agonist
stimulation experiments, 50&nbsp;&#181;g of cell membranes were incubated in
triplicate with 10&nbsp;&#181;<font size=-1>M</font> GDP and increasing concentrations<SUP> </SUP>of agonist in a final volume of 0.9&nbsp;ml of buffer (20&nbsp;m<font size=-1>M</font>
HEPES,<SUP> </SUP>10&nbsp;m<font size=-1>M</font> MgCl<SUB>2</SUB>, 100&nbsp;m<font size=-1>M</font> NaCl, pH
7.4) for 30&nbsp;min at 30&nbsp;&#176;C as described<SUP> </SUP>by Gardner <I>et al</I>.
(<A HREF="#B23">23-25</A>). 0.1&nbsp;ml of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S (1,250&nbsp;Ci/mmol) was
added to a final concentration of<SUP> </SUP>100&nbsp;p<font size=-1>M</font> and the incubation
continued for a further 20&nbsp;min. Basal<SUP> </SUP>levels of
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding were defined as that in the absence
of agonist.<SUP> </SUP>Incubations were terminated by rapid filtration through
Whatman<SUP> </SUP>GF/B glass fiber filters using a Brandel cell harvester with
four<SUP> </SUP>washes of 4&nbsp;ml of phosphate-buffered saline, and radioactivity<SUP> </SUP>determined as above. When different agonists were tested, a 1<SUP>&nbsp;</SUP>m<font size=-1>M</font> dopamine control was always present in the assay to
allow relative<SUP> </SUP>efficacy determinations to be<SUP> </SUP>made.
<P>
In saturation binding experiments, 40&nbsp;&#181;g of cell membranes was
incubated in triplicate with 10&nbsp;&#181;<font size=-1>M</font> GDP, 100&nbsp;p<font size=-1>M</font> [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S, 100&nbsp;p<font size=-1>M</font>-100
n<font size=-1>M</font> GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S in the absence or presence of 1&nbsp;m<font size=-1>M</font><SUP> </SUP>dopamine in a final volume of 1&nbsp;ml of buffer for 2&nbsp;h at 30&nbsp;&#176;C.<SUP> </SUP>Dopamine-stimulated [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding was obtained by
subtraction, and total dopamine-stimulated<SUP> </SUP>GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding was
determined as dpm bound&nbsp;&#215;&nbsp;([total
GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S]/[[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S]).



    

    


<P><I>Determination of G Protein Level Using Quantitative Western
Blot--</I>

Before analysis, proteins (Sf21 membranes or pure G
protein subunits) were denatured by the addition of 10&nbsp;&#181;l of
electrophoresis<SUP> </SUP>loading buffer (100&nbsp;m<font size=-1>M</font> Tris-Cl, 200&nbsp;m<font size=-1>M</font> dithiothreitol, 4% SDS,<SUP> </SUP>0.2% bromphenol blue, 20%
glycerol) and heated at 90&nbsp;&#176;C for 5<SUP>&nbsp;</SUP>min. Sf21 membrane
proteins (20-40 &#181;g) and G protein standards<SUP> </SUP>were separated by
SDS-polyacrylamide gel electrophoresis on 12%<SUP> </SUP>acrylamide gels. Samples
were then transferred to nitrocellulose<SUP> </SUP>membranes using the Bio-Rad
semidry transfer system. Nitrocellulose<SUP> </SUP>membranes were incubated for
1&nbsp;h with 5% dried milk (w/v) in buffer<SUP> </SUP>(137&nbsp;m<font size=-1>M</font> NaCl,
3&nbsp;m<font size=-1>M</font> KCl, 25&nbsp;m<font size=-1>M</font> Tris-Cl, 0.1% Tween).
Membranes<SUP> </SUP>were then incubated overnight at 4&nbsp;&#176;C with single primary
antibodies<SUP> </SUP>(monoclonal antibody 3073&nbsp;anti-<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>o</SUB>, 1&nbsp;&#181;g/ml
(Chemicon); C-10 anti-<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>1-3</SUB>,<SUP> </SUP>1&nbsp;&#181;g/ml (Santa Cruz, see
Fig. <a href="#F2">2</a>); monoclonal antibody 3077&nbsp;anti-<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>i2</SUB>,<SUP> </SUP>1&nbsp;&#181;g/ml
(Chemicon, see Fig. <a href="#F3">3</a>); C-16 anti-<IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>1</SUB>, 0.4&nbsp;&#181;g/ml (Santa<SUP> </SUP>Cruz); A-16 anti-<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "><SUB>2</SUB>, 0.4&nbsp;&#181;g/ml (Santa Cruz)) in buffer
containing<SUP> </SUP>5% dried milk (w/v). Membranes were washed five times with
buffer<SUP> </SUP>(10&nbsp;min each) and then incubated with secondary antibody
(anti-mouse<SUP> </SUP>(<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>o</SUB>, <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>i2</SUB>)/rabbit
(<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>i1-3</SUB>, <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>1</SUB>, <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "><SUB>2</SUB>) immunoglobin
horseradish<SUP> </SUP>peroxidase conjugate (Sigma, 1:5,000)) for 1&nbsp;h.
Membranes were<SUP> </SUP>then washed three times (10&nbsp;min each) with buffer before
exposure<SUP> </SUP>to equal volumes of Enhanced Chemiluminescence (ECL) detection<SUP> </SUP>reagents 1&nbsp;and 2&nbsp;(<a href="/cgi/inline?Amersham%20Pharmacia%20Biotech">Amersham Pharmacia Biotech</a>). Membranes were<SUP> </SUP>then
wrapped in Clingfilm and exposed to Hybond-ECL x-ray film<SUP> </SUP>for between
30&nbsp;s and 2&nbsp;min. Densitometry was performed using a<SUP> </SUP>GS710
calibrated imaging densitometer (Bio-Rad), and data were<SUP> </SUP>analyzed using
GraphPad Prism. Determinations of levels of G protein<SUP> </SUP>subunits were
always performed using ECL exposures that ensured<SUP> </SUP>a linear dependence
of band density on protein<SUP> </SUP>amount.
<P>
In some experiments membranes were extracted with 1% cholate, 1&nbsp;<font size=-1>M</font> NaCl (10&nbsp;mg of membranes/ml of cholate/NaCl) for 1&nbsp;h
at<SUP> </SUP>4&nbsp;&#176;C. The mixture was centrifuged at 4,500&nbsp;&#215;&nbsp;<I>g</I>
for 5&nbsp;min at 4<SUP> </SUP>&#176;C, and the supernatant and pellet were collected.
These were<SUP> </SUP>then analyzed using Western blotting as above, the pellet
having<SUP> </SUP>been dissolved in 1% cholate, 1% Nonidet P-40, and 1&nbsp;<font size=-1>M</font><SUP> </SUP>NaCl.



    


    


    
    


<BR><BR CLEAR=ALL>


<A NAME="SEC2"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;RESULTS</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">INTRODUCTION</A>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>RESULTS</FONT>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>


    



    



    


<P><I>Expression of D<SUB>2</SUB> Dopamine Receptors in Sf21
Cells--</I>

D<SUB>2</SUB> dopamine receptors were expressed in
Sf21 insect cells using the baculovirus expression system. The
expressed receptors<SUP> </SUP>were characterized using ligand binding with
[<SUP>3</SUP>H]spiperone. Saturation analyses of
[<SUP>3</SUP>H]spiperone binding (1-ml assay volume) gave a
<I>K</I><SUB><I>d</I></SUB> of<SUP> </SUP>145&nbsp;p<font size=-1>M</font> (p<I>K<SUB>d</SUB></I>
9.84&nbsp;&#177;&nbsp;0.03,&nbsp;mean&nbsp;&#177;&nbsp;S.E., <I>n</I>&nbsp;=&nbsp;3) and a
<I>B</I><SUB>max</SUB> of ~2<SUP> </SUP>pmol/mg. When these assays were
repeated in a 10-ml format a similar<SUP> </SUP><I>K</I><SUB><I>d</I></SUB> was observed
(171&nbsp;p<font size=-1>M</font> (p<I>K<SUB>d</SUB></I> 9.77&nbsp;&#177;&nbsp;0.21,&nbsp;mean&nbsp;&#177;&nbsp;S.E.,<SUP> </SUP><I>n</I>&nbsp;=&nbsp;3)). The similarity of the
<I>K</I><SUB><I>d</I></SUB> values from 1-ml and<SUP> </SUP>10-ml assays demonstrates
that radioligand depletion artifacts<SUP> </SUP>are absent from the assays
(<A HREF="#B26">26</A>).
<P>
A series of antagonists exhibited competition curves <I>versus</I>
[<SUP>3</SUP>H]spiperone which were best fitted by one-binding site
models.<SUP> </SUP>The derived <I>K</I><SUB><I>i</I></SUB> values are given in Table
<a href="#TI">I</a> for experiments<SUP> </SUP>using buffer containing
sodium ions and where the sodium had been<SUP> </SUP>replaced by NMDG</A> to maintain
ionic strength. The rank order of<SUP> </SUP><I>K</I><SUB><I>i</I></SUB> values is
similar to that observed for the D<SUB>2</SUB> receptor<SUP> </SUP>expressed in
other systems, so the receptor is being expressed<SUP> </SUP>with fidelity in the
present experiments. The substituted benzamide<SUP> </SUP>antagonists,
<I>e.g.</I> sulpiride, are sensitive to the removal of sodium<SUP> </SUP>ions
in these assays. Some data are also given for these drugs<SUP> </SUP>when binding
to D<SUB>2</SUB> receptors expressed in CHO</A> cells. In the presence<SUP> </SUP>of
sodium ions <I>K</I><SUB><I>i</I></SUB> values are similar for the receptor<SUP> </SUP>expressed in the two cell backgrounds, whereas upon removal of<SUP> </SUP>sodium
ions, binding of substituted benzamide drugs is of lower<SUP> </SUP>affinity for
the receptors expressed in Sf21 cells.

<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF><NOBR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</NOBR><BR><NOBR><STRONG>View this table:</STRONG></NOBR>
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/TI">[in this window]</A></NOBR><BR>
<NOBR><A HREF="/cgi/content-nw/full/276/31/28667/TI"
	onClick="startTarget('TI', 500, 400); this.href='/cgi/content-nw/full/276/31/28667/TI'"
	onMouseOver="window.status='View table in a separate window';
		return true"
TARGET='TI'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="TI"><!-- TABLE I --></A>
<CENTER>
<B>Table I</B><BR>
<STRONG>

    Binding of drugs to D<SUB><I>2</I></SUB> dopamine receptors expressed in
Sf21 and CHO</A> cells

<BR>
</STRONG>
</CENTER>
Competition experiments <I>versus</I> [<SUP>3</SUP>H]spiperone for
various substances were performed as described under "Experimental
Procedures," and <I>K</I><SUB><I>i</I></SUB> values (p<I>K</I><SUB><I>i</I></SUB>&nbsp;&#177;&nbsp;S.E., <I>K</I><SUB><I>i</I></SUB> from three or more experiments) were
derived from the best fit curves to one-binding site models.

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>



<P>
Competition binding experiments were also performed with the agonists
<I>N</I>-propyl norapomorphine (NPA</A>) and dopamine and, except<SUP> </SUP>in
one experiment with NPA</A>, the data fitted best to a single-binding<SUP> </SUP>site
model, and there was no significant effect of the addition<SUP> </SUP>of 100&nbsp;&#181;<font size=-1>M</font> GTP (see Table <a href="#TIII">III</a>). Formation of receptor-G protein<SUP> </SUP>complexes cannot, therefore, be detected in this way. Also, dopamine<SUP> </SUP>stimulation of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding could not be detected
in membranes expressing<SUP> </SUP>the D<SUB>2</SUB> receptor without exogenous G
proteins, whereas (see below)<SUP> </SUP>this activity was clearly present in
membranes expressing exogenous<SUP> </SUP>G protein. The D<SUB>2</SUB> dopamine
receptor does not, therefore, interact<SUP> </SUP>strongly with the endogenous G
proteins of Sf21 cells. Similarly,<SUP> </SUP>when the formyl peptide
receptor was expressed in Sf 9&nbsp;insect<SUP> </SUP>cells no agonist stimulation of
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding to the endogenous G proteins could
be detected<SUP> </SUP>(<A HREF="#B27">27</A>).



    

    


<P><I>Coexpression of D<SUB>2</SUB> Dopamine Receptors and G Proteins in
Sf21 Cells--</I>

In these experiments the D<SUB>2</SUB>
dopamine receptor was expressed in Sf21 cells together with G
protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">, <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta ">, and <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">&nbsp;subunits. The<SUP> </SUP>G protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunits
(<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>o</SUB> and <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>i2</SUB>) were used because the
D<SUB>2</SUB> receptor<SUP> </SUP>has been reported to interact with these (<A HREF="#B13">13</A>).
The <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>1</SUB> and <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "><SUB>2</SUB><SUP> </SUP>subunits were used for all of
the studies here because these subunits<SUP> </SUP>support coupling between
several receptors and G protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunits<SUP> </SUP>(<A HREF="#B27">27-31</A>). In preliminary
experiments, different multiplicity of<SUP> </SUP>infection values for the
different baculoviruses containing the<SUP> </SUP>four proteins were tested to
obtain similar receptor expression<SUP> </SUP>levels and a high
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding response to dopamine. Based on these
findings<SUP> </SUP>(data not shown), in the experiments described below,
multiplicity<SUP> </SUP>of infection values were used as follows: for membranes
expressing<SUP> </SUP>G<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>i2</SUB>,
receptor/<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>i2</SUB>/<IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>1</SUB>/<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "><SUB>2</SUB>-2/2/1/1;
for membranes expressing G<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>o</SUB>,<SUP> </SUP>receptor/<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>o</SUB>/<IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>1</SUB>/<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "><SUB>2</SUB>-3/1/1/1.
<P>
The levels of D<SUB>2</SUB> receptor were determined in the membranes
using saturation analyses with [<SUP>3</SUP>H]spiperone (Fig.
<a href="#F1">1</a> and Table
<a href="#TII">II</a>). Levels of D<SUB>2</SUB> dopamine
receptor<SUP> </SUP>were similar in the two preparations, and there was no
significant<SUP> </SUP>difference in the radioligand affinity. The affinity for
[<SUP>3</SUP>H]spiperone binding was unaffected by the addition of
100&nbsp;&#181;<font size=-1>M</font> GTP<SUP> </SUP>in both preparations and was not significantly
different from<SUP> </SUP>that for the receptor expressed alone.



<BR CLEAR=ALL><A NAME="F1"><!-- FIG 1 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/31/28667/F1">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=187 HEIGHT=200 SRC="/content/vol276/issue31/images/small/bc3013321001.gif"></A><BR>

<STRONG>View larger version</STRONG> (23K):
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/F1">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/31/28667/F1"
onClick="startTarget('F1', 561, 640); this.href='/cgi/content-nw/full/276/31/28667/F1'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F1">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 1. &nbsp;</STRONG>

<B>Saturation analyses for
[<SUP>3</SUP>H]spiperone and
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding in membranes
of Sf21 cells expressing D<SUB>2</SUB> dopamine receptors and G
proteins.</B> [<SUP>3</SUP>H]Spiperone and
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S saturation binding experiments were
performed on membranes expressing D<SUB>2</SUB> dopamine receptors and
either G<SUB>o</SUB> (<I>panels A</I>, <I>C</I>, and
<I>E</I>) or G<SUB>i2</SUB> (<I>panels B</I>, <I>D</I>,
and <I>F</I>) as described under "Experimental Procedures." In
<I>panels C</I> and <I>D</I> data are given for
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding in the absence (<IMG SRC="/math/12pt/normal/bigcir.gif" ALIGN=BOTTOM ALT="open circle ">) and presence
(<IMG SRC="/math/12pt/normal/atyp0265.gif">) of 1&nbsp;m<font size=-1>M</font> dopamine. The dopamine-stimulated
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding was determined by subtraction and
was corrected for the added nonradioactive GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S as described under
"Experimental Procedures" to give the data in <I>panels E</I>
and <I>F</I>. Data are from representative experiments replicated
as in Table <a href="#TI">I</a>, and the curves in <I>panels A</I>, <I>B</I>,
<I>E</I>, and <I>F</I> are best fit curves to one-site binding
models.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 1 -->





<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF><NOBR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</NOBR><BR><NOBR><STRONG>View this table:</STRONG></NOBR>
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/TII">[in this window]</A></NOBR><BR>
<NOBR><A HREF="/cgi/content-nw/full/276/31/28667/TII"
	onClick="startTarget('TII', 500, 400); this.href='/cgi/content-nw/full/276/31/28667/TII'"
	onMouseOver="window.status='View table in a separate window';
		return true"
TARGET='TII'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="TII"><!-- TABLE II --></A>
<CENTER>
<B>Table II</B><BR>
<STRONG>

    Expression of D<SUB><I>2</I></SUB> dopamine receptors and G proteins in
Sf21 cells

<BR>
</STRONG>
</CENTER>
D<SUB>2</SUB> dopamine receptors were expressed together with G protein
subunits as described under "Experimental Procedures," and
saturation binding analyses using [<SUP>3</SUP>H]spiperone were
performed to determine levels of D<SUB>2</SUB> receptor. Binding
parameters (<I>K</I><SUB><I>d</I></SUB> and <I>B</I><SUB>max</SUB>) were
derived from the data, and values are expressed as the mean&nbsp;&#177;&nbsp;S.E. (<A HREF="#B3">3</A>). G protein levels were determined using quantitative Western
blot and are expressed as the mean&nbsp;&#177;&nbsp;S.E. (<A HREF="#B3">3-4</A>). Neither
D<SUB>2</SUB> receptor nor G protein levels were significantly different
in the two preparations (<I>p</I>&nbsp;&gt;&nbsp;0.05).
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S saturation binding assays were performed, and
<I>K</I><SUB><I>d</I></SUB> and <I>B</I><SUB>max</SUB> values are given;
these were not significantly different between the two preparations
(<I>p</I>&nbsp;&gt;&nbsp;0.05).

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>



<P>
The levels of G protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">, <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta ">, and <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">&nbsp;subunits were determined by
quantitative Western blot, and the levels were not significantly<SUP> </SUP>different in the two preparations (Table <a href="#TII">II</a>). Representative blots<SUP> </SUP>are
shown in Fig. <a href="#F2">2</a>. Levels of <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunits
were also determined<SUP> </SUP>after extraction of the membranes with 1%
cholate. In each preparation<SUP> </SUP>60-70% of the <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunit was found in
the cholate extract, suggesting<SUP> </SUP>that the majority of the expressed
subunits were fully active<SUP> </SUP>(Fig. <a href="#F3">3</a>).
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S saturation binding assays in the presence of
dopamine<SUP> </SUP>were also performed in the two preparations, and these showed<SUP> </SUP><I>B</I><SUB>max</SUB> and <I>K</I><SUB><I>d</I></SUB> values for
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding which were not significantly
different (Table<SUP> </SUP><a href="#TII">II</a> and Fig. <a href="#F1">1</a>).



<BR CLEAR=ALL><A NAME="F2"><!-- FIG 2 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/31/28667/F2">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=156 HEIGHT=200 SRC="/content/vol276/issue31/images/small/bc3013321002.gif"></A><BR>

<STRONG>View larger version</STRONG> (27K):
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/F2">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/31/28667/F2"
onClick="startTarget('F2', 493, 640); this.href='/cgi/content-nw/full/276/31/28667/F2'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F2">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 2. &nbsp;</STRONG>

<B>Determination of G protein levels by
quantitative Western blot.</B> Samples of membranes expressing
receptor and G proteins were analyzed by Western blot together with
known amounts of pure G protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">, <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta ">, or <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">&nbsp;subunit as described
under "Experimental Procedures." Representative blots are shown for
the preparations containing G<SUB>o</SUB> and G<SUB>i2</SUB>. The
amount of G protein expressed was calculated, and the mean values from
replicate experiments are given in Table <a href="#TII">II</a>. In <I>panels A</I> and
<I>B lanes 1-3</I> contain 0.5,&nbsp;0.25,&nbsp;and 0.1&nbsp;&#181;g of
pure G protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunit, respectively (<I>panel A</I>,
<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>o</SUB>; <I>panel B</I>, <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>i2</SUB>), and
<I>lane 4</I>&nbsp;contains 20&nbsp;&#181;g of membrane protein. In <I>panel
C</I> (<I>lanes 1-4</I>) 0.3,&nbsp;0.2,&nbsp;0.1,&nbsp;and 0.05&nbsp;&#181;g of pure
<IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "> dimer, respectively, was analyzed, and <I>lanes 5</I>&nbsp;and
<I>6</I>&nbsp;contain 20&nbsp;&#181;g of membrane protein (<I>lane 5</I>,
G<SUB>o</SUB>; <I>lane 6</I>, G<SUB>i2</SUB>), and the blot was
probed for the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>1</SUB> subunit. In <I>panel D</I>
(<I>lanes 1-4</I>) 0.15,&nbsp;0.05,&nbsp;0.025,&nbsp;and 0.0125&nbsp;&#181;g of pure
<IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "> dimer, respectively, was analyzed, and <I>lanes 5</I>&nbsp;and
<I>6</I>&nbsp;contain 40&nbsp;&#181;g of membrane protein (<I>lane 5</I>,
G<SUB>o</SUB>; <I>lane 6</I>, G<SUB>i2</SUB>), and the blot was
probed for the <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "><SUB>2</SUB> subunit.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 2 -->







<BR CLEAR=ALL><A NAME="F3"><!-- FIG 3 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/31/28667/F3">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=200 HEIGHT=170 SRC="/content/vol276/issue31/images/small/bc3013321003.gif"></A><BR>

<STRONG>View larger version</STRONG> (54K):
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/F3">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/31/28667/F3"
onClick="startTarget('F3', 590, 575); this.href='/cgi/content-nw/full/276/31/28667/F3'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F3">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 3. &nbsp;</STRONG>

<B>Extraction of G protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunits by cholate.</B> Membranes from preparations expressing
G<SUB>o</SUB> or G<SUB>i2</SUB> were extracted with 1% cholate as
described under "Experimental Procedures," and the levels of G
protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunit were determined as in Fig. <a href="#F2">2</a>. In <I>panels
A</I> and <I>B</I>, <I>lanes 1-5</I> contain 1,&nbsp;0.5,&nbsp;0.1,&nbsp;0.05,&nbsp;and 0.01&nbsp;&#181;g of pure G protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunit, respectively
(<I>panel A</I>, <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>o</SUB>; <I>panel B</I>,
<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>i2</SUB>), and <I>lanes 6</I>&nbsp;and <I>7</I>&nbsp;contain,
respectively, the supernatant and pellet from the cholate extract
(equivalent to 100&nbsp;&#181;g of membrane protein). The distribution of <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunit in the two preparations was: G<SUB>o</SUB> supernatant,
68&nbsp;&#177;&nbsp;5%; pellet, 32&nbsp;&#177;&nbsp;5%; G<SUB>i2</SUB> supernatant,
59&nbsp;&#177;&nbsp;8%; pellet, 41&nbsp;&#177;&nbsp;8% (mean&nbsp;&#177;&nbsp;S.E. (<A HREF="#B3">3</A>)).


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 3 -->







    

    


<P><I>Agonist Binding to D<SUB>2</SUB> Dopamine Receptors Coexpressed
with G Proteins--</I>

The binding of agonists to D<SUB>2</SUB>
dopamine receptors was determined in competition with
[<SUP>3</SUP>H]spiperone in the preparations containing
G<SUB>o</SUB> and G<SUB>i2</SUB>. Competition<SUP> </SUP>curves for several
agonists (NPA</A>, dopamine, (+)-3-PPP, <I>m</I>-tyramine),<SUP> </SUP>in both
preparations, were best fitted by a two-site binding model<SUP> </SUP>with
20-30% higher affinity sites (Figs. <a href="#F4">4</a>
and <a href="#F5">5</a>; Table <a href="#TIII">III</a>). The<SUP> </SUP>proportion of higher affinity sites for a
ligand did not differ<SUP> </SUP>significantly between the two preparations.
Competition experiments<SUP> </SUP>for dopamine and NPA</A> were also performed in the
presence of 100<SUP>&nbsp;</SUP>&#181;<font size=-1>M</font> GTP, and competition curves under
these conditions were best<SUP> </SUP>described by one-binding site models; the
affinity in the presence<SUP> </SUP>of GTP was similar to that of the lower
affinity site observed<SUP> </SUP>in the absence of GTP and also similar to that
observed in preparations<SUP> </SUP>expressing receptor alone. For (<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP,
data obtained in the<SUP> </SUP>preparation containing G<SUB>o</SUB> were also
fitted best to a two-site<SUP> </SUP>model. For other agonists in both
preparations (bromocriptine<SUP> </SUP>and <I>p</I>-tyramine) and for
(<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP in the preparation containing<SUP> </SUP>G<SUB>i2</SUB> the
competition curves were best fitted by a one-binding site<SUP> </SUP>model. When
<I>K</I><SUB><I>i</I></SUB> values for the different sites were compared<SUP> </SUP>between the two preparations there were significant differences<SUP> </SUP>for
some agonists (NPA</A>, <I>m</I>-tyramine) at the higher affinity site,<SUP> </SUP>but for other agonists affinities at this site were not significantly<SUP> </SUP>different. Affinities at the lower affinity site and for the single<SUP> </SUP>affinity site seen for some agonists were not significantly different<SUP> </SUP>between the two preparations.



<BR CLEAR=ALL><A NAME="F4"><!-- FIG 4 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/31/28667/F4">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=146 HEIGHT=200 SRC="/content/vol276/issue31/images/small/bc3013321004.gif"></A><BR>

<STRONG>View larger version</STRONG> (19K):
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/F4">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/31/28667/F4"
onClick="startTarget('F4', 472, 640); this.href='/cgi/content-nw/full/276/31/28667/F4'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F4">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 4. &nbsp;</STRONG>

<B>Binding of agonists to membranes of
Sf21 cells expressing D<SUB>2</SUB> dopamine receptors and G
proteins.</B> The binding of dopamine (<IMG SRC="/math/12pt/normal/atyp0265.gif">), bromocriptine (<IMG SRC="/math/12pt/normal/dtri.gif" ALIGN=BOTTOM ALT="down-triangle">), and
(<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP (<IMG SRC="/math/12pt/normal/bigcir.gif" ALIGN=BOTTOM ALT="open circle ">) to membranes expressing D<SUB>2</SUB> receptor and
either G<SUB>o</SUB> (<I>panel A</I>) or G<SUB>i2</SUB>
(<I>panel B</I>) was determined in competition <I>versus</I>
[<SUP>3</SUP>H]spiperone as described under "Experimental
Procedures." Data shown are from representative experiments
replicated as in Table <a href="#TII">II</a>, and the curves are the best fit curves to
one-site (R/G<SUB>o</SUB>, <IMG SRC="/math/12pt/normal/dtri.gif" ALIGN=BOTTOM ALT="down-triangle">; R/G<SUB>i2</SUB>, <IMG SRC="/math/12pt/normal/dtri.gif" ALIGN=BOTTOM ALT="down-triangle">, <IMG SRC="/math/12pt/normal/bigcir.gif" ALIGN=BOTTOM ALT="open circle ">) or
two-site models (R/G<SUB>o</SUB>, <IMG SRC="/math/12pt/normal/bigcir.gif" ALIGN=BOTTOM ALT="open circle ">, <IMG SRC="/math/12pt/normal/atyp0265.gif">; R/G<SUB>i2</SUB>,
<IMG SRC="/math/12pt/normal/atyp0265.gif">).


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 4 -->







<BR CLEAR=ALL><A NAME="F5"><!-- FIG 5 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/31/28667/F5">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=115 HEIGHT=200 SRC="/content/vol276/issue31/images/small/bc3013321005.gif"></A><BR>

<STRONG>View larger version</STRONG> (13K):
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/F5">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/31/28667/F5"
onClick="startTarget('F5', 404, 640); this.href='/cgi/content-nw/full/276/31/28667/F5'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F5">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 5. &nbsp;</STRONG>

<B>Binding of agonists to membranes of
Sf21 cells expressing D<SUB>2</SUB> dopamine receptors and G
proteins.</B> The binding of NPA</A> to membranes expressing
D<SUB>2</SUB> receptor and either G<SUB>o</SUB> (<I>panel A</I>)
or G<SUB>i2</SUB> (<I>panel B</I>) was determined in competition
<I>versus</I> [<SUP>3</SUP>H]spiperone in the absence (<IMG SRC="/math/12pt/normal/bigcir.gif" ALIGN=BOTTOM ALT="open circle ">) or
presence (<IMG SRC="/math/12pt/normal/atyp0265.gif">) of 100&nbsp;&#181;<font size=-1>M</font> GTP as described under
"Experimental Procedures." Data shown are from representative
experiments replicated as in Table <a href="#TII">II</a>, and the curves are the best fit
curves to one-site (<IMG SRC="/math/12pt/normal/atyp0265.gif">) or two-site models (<IMG SRC="/math/12pt/normal/bigcir.gif" ALIGN=BOTTOM ALT="open circle ">).


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 5 -->





<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF><NOBR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</NOBR><BR><NOBR><STRONG>View this table:</STRONG></NOBR>
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/TIII">[in this window]</A></NOBR><BR>
<NOBR><A HREF="/cgi/content-nw/full/276/31/28667/TIII"
	onClick="startTarget('TIII', 500, 400); this.href='/cgi/content-nw/full/276/31/28667/TIII'"
	onMouseOver="window.status='View table in a separate window';
		return true"
TARGET='TIII'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="TIII"><!-- TABLE III --></A>
<CENTER>
<B>Table III</B><BR>
<STRONG>

    Agonist binding to D<SUB><I>2</I></SUB> dopamine receptors expressed in
Sf21 cells

<BR>
</STRONG>
</CENTER>
Competition experiments <I>versus</I> [<SUP>3</SUP>H]spiperone were
used to derive the binding parameters from the best fit curves
(<I>K</I><SUB><I>i</I></SUB> from one-binding site models and
<I>K</I><SUB><I>h</I></SUB>, <I>K</I><SUB><I>l</I></SUB>, and percent high affinity
sites from two-binding site models) for experiments using membranes
expressing D<SUB>2</SUB> receptors and G proteins. Data are expressed as
the mean&nbsp;&#177;&nbsp;S.E. from three or more experiments. In preparations
of membranes that had been infected only with the baculovirus coding
for D<SUB>2</SUB> receptor, the following values were obtained: dopamine
<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">GTP (4.80&nbsp;&#177;&nbsp;0.13&nbsp;(16&nbsp;&#181;<font size=-1>M</font>)) +GTP (4.83&nbsp;&#177;&nbsp;0.08&nbsp;(15&nbsp;&#181;<font size=-1>M</font>)); NPA</A> <IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">GTP (7.51&nbsp;&#177;&nbsp;0.19&nbsp;(31&nbsp;n<font size=-1>M</font>)) +GTP (7.11&nbsp;&#177;&nbsp;0.10&nbsp;(77&nbsp;n<font size=-1>M</font>))
(competition curves fit best to a one binding site model).

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>






    

    


<P><I>Stimulation of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S Binding by
Agonists--</I>

G protein activation by agonists in the two preparations
was assessed by determining agonist-stimulated
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding (Fig.
<a href="#F6">6</a>). These assays were conducted in the
presence<SUP> </SUP>of 10&nbsp;&#181;<font size=-1>M</font> GDP to suppress basal
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding and to observe agonist stimulation
of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding over the basal level (<A HREF="#B23">23-25</A>).
Basal levels of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding may be high in this
system because of the high<SUP> </SUP>levels of G protein <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunit expression.
Under these conditions<SUP> </SUP>(<I>i.e.</I> in the presence of 10&nbsp;&#181;<font size=-1>M</font> GDP), full agonists lead to an<SUP> </SUP>approximate doubling of
the rate of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding relative to the basal
rate in both preparations.<SUP> </SUP>The EC<SUB>50</SUB> values and maximal
effects for a range of agonists are<SUP> </SUP>given in Table
<a href="#TIV">IV</a>, and there are significant differences
between<SUP> </SUP>the preparations containing G<SUB>o</SUB> and G<SUB>i2</SUB>.
Several compounds stimulated<SUP> </SUP>[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding to the
same or greater extent than dopamine in<SUP> </SUP>both preparations. Four
agonists (<I>m</I>-tyramine, <I>p</I>-tyramine, (+)-3-PPP,<SUP> </SUP>(<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP), gave greater maximal stimulation in the preparation<SUP> </SUP>containing G<SUB>o</SUB> compared with the preparation containing
G<SUB>i2</SUB>. Indeed,<SUP> </SUP>two of the compounds (<I>p</I>-tyramine
and (<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP) were unable to<SUP> </SUP>stimulate [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S
binding in the preparation containing G<SUB>i2</SUB>. In addition<SUP> </SUP>to
these differences in maximal stimulation, there were also significant<SUP> </SUP>differences (4-16-fold) in the EC<SUB>50</SUB> values for the
stimulation<SUP> </SUP>of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding between the two
preparations for all the compounds<SUP> </SUP>tested, with the exception of
bromocriptine.



<BR CLEAR=ALL><A NAME="F6"><!-- FIG 6 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/31/28667/F6">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=151 HEIGHT=200 SRC="/content/vol276/issue31/images/small/bc3013321006.gif"></A><BR>

<STRONG>View larger version</STRONG> (22K):
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/F6">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/31/28667/F6"
onClick="startTarget('F6', 483, 640); this.href='/cgi/content-nw/full/276/31/28667/F6'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F6">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 6. &nbsp;</STRONG>

<B>Stimulation of
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding by agonists in
membranes of Sf21 cells expressing D<SUB>2</SUB> dopamine
receptors and G proteins.</B> The stimulation of
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding by agonists was determined as
described under "Experimental Procedures" in membranes expressing
D<SUB>2</SUB> receptor and either G<SUB>o</SUB> (<I>panel A</I>)
or G<SUB>i2</SUB> (<I>panel B</I>). Agonists used were as follows:
bromocriptine (<IMG SRC="/math/12pt/normal/atyp0244.gif">), dopamine (<IMG SRC="/math/12pt/normal/diams.gif" ALIGN=BOTTOM ALT="black-diamond ">), NPA</A> (<IMG SRC="/math/12pt/normal/squarf.gif" ALIGN=BOTTOM ALT="black-square">), quinpirole (<IMG SRC="/math/12pt/normal/dtrif.gif" ALIGN=BOTTOM ALT="black-down-triangle ">),
<I>m</I>-tyramine (<IMG SRC="/math/12pt/normal/utri.gif" ALIGN=BOTTOM ALT="triangle ">), <I>p</I>-tyramine (<IMG SRC="/math/12pt/normal/dtri.gif" ALIGN=BOTTOM ALT="down-triangle">), (<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP
(<IMG SRC="/math/12pt/normal/bigcir.gif" ALIGN=BOTTOM ALT="open circle ">), and (+)-3-PPP (<IMG SRC="/math/12pt/normal/dtrif.gif" ALIGN=BOTTOM ALT="black-down-triangle ">). The data are representative stimulation
curves replicated as in Table <a href="#TIV">IV</a>.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 6 -->





<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF><NOBR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</NOBR><BR><NOBR><STRONG>View this table:</STRONG></NOBR>
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/TIV">[in this window]</A></NOBR><BR>
<NOBR><A HREF="/cgi/content-nw/full/276/31/28667/TIV"
	onClick="startTarget('TIV', 500, 400); this.href='/cgi/content-nw/full/276/31/28667/TIV'"
	onMouseOver="window.status='View table in a separate window';
		return true"
TARGET='TIV'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="TIV"><!-- TABLE IV --></A>
<CENTER>
<B>Table IV</B><BR>
<STRONG>

    Agonist stimulation of [<SUP><I>35</I></SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding via D<SUB><I>2</I></SUB>
dopamine receptors expressed in Sf21 cells

<BR>
</STRONG>
</CENTER>
The stimulation of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding in membranes
expressing D<SUB>2</SUB> receptors and G proteins was determined as
described under "Experimental Procedures." The maximum response
(relative to dopamine) and the EC<SUB>50</SUB> were determined. Data are
expressed as the mean&nbsp;&#177;&nbsp;S.E. from three or more experiments.

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>






    


    


    
    


<BR><BR CLEAR=ALL>


<A NAME="SEC3"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;DISCUSSION</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">INTRODUCTION</A>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">RESULTS</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>DISCUSSION</FONT>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>


    
    <P>In this study we have expressed the D<SUB>2</SUB> dopamine
receptor together with the G proteins G<SUB>o</SUB> and
G<SUB>i2</SUB> in insect cells using the<SUP> </SUP>baculovirus system. We show
that the D<SUB>2</SUB> receptor interacts more<SUP> </SUP>strongly with
G<SUB>o</SUB> than G<SUB>i2</SUB> and that this influences the
functional<SUP> </SUP>selectivity of agonist signaling. We also show that the
extent<SUP> </SUP>of the selectivity of the interaction between the D<SUB>2</SUB>
receptor<SUP> </SUP>and G<SUB>o</SUB> or G<SUB>i2</SUB> depends on the agonist
used. Thus, agonists may<SUP> </SUP>stabilize different conformations of the
receptor with different<SUP> </SUP>abilities to interact with and activate G
proteins. This is the<SUP> </SUP>first study to address this issue for the
D<SUB>2</SUB> dopamine receptor<SUP> </SUP>in a fully defined<SUP> </SUP>system.
    
    </P>

    
    <P>The levels of receptor (R) and G protein (G) subunits
(<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>o</SUB>/<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>i2</SUB>, and <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>1</SUB> and
<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "><SUB>2</SUB>) in the preparations expressing G<SUB>o</SUB> and
G<SUB>i2</SUB> were<SUP> </SUP>determined using saturation analysis with the
radioligand [<SUP>3</SUP>H]spiperone and quantitative Western blot,
respectively. The levels<SUP> </SUP>of <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunit detected were similar to those
reported in other<SUP> </SUP>studies on expression of receptors and G<SUB>i</SUB>
or G<SUB>s</SUB> proteins in insect<SUP> </SUP>cells (<A HREF="#B27">27</A>, <A HREF="#B32">32</A>). The
<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "><SUB>2</SUB> subunit was expressed at lower levels<SUP> </SUP>than either the
<IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>1</SUB> or <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunits and so may limit the levels of<SUP> </SUP>G
protein heterotrimers. Membranes were also extracted with 1%<SUP> </SUP>cholate
because this has been proposed to extract active G protein<SUP> </SUP>(<A HREF="#B33">33-36</A>); in
each preparation 60-70% of the <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunit was extractable.<SUP> </SUP>Based on
these values and the limiting level of <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma "><SUB>2</SUB> subunit, there<SUP> </SUP>was a ratio of heterotrimeric G protein to receptor of ~20-fold<SUP> </SUP>in
both preparations. This ratio is comparable with to obtained<SUP> </SUP>in other
studies on expression of receptors and G proteins. G/R<SUP> </SUP>ratios of
~30-100 have been reported in insect cells (<A HREF="#B27">27</A>, <A HREF="#B31">31</A>,<SUP> </SUP><A HREF="#B32">32</A>), and G/R
ratios of ~50 have been reported for <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>2</SUB> adrenergic<SUP> </SUP>receptors in platelets (<A HREF="#B37">37</A>) and ~100 for <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta ">-adrenergic receptors<SUP> </SUP>in
lymphoma cells (<A HREF="#B38">38</A>).
    
    </P>

    
    <P>[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S saturation binding assays were performed in
the two preparations. These assays have been used by others to assess<SUP> </SUP>G
protein levels (see, <I>e.g.</I> Ref. <A HREF="#B39">39</A>). In the present system,<SUP> </SUP>[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S saturation binding assays gave similar
values for the<SUP> </SUP>level of dopamine-stimulated [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S
binding in the two preparations. The levels determined<SUP> </SUP>by
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding are low compared with the numbers of
G proteins<SUP> </SUP>measured by quantitative Western blot. This is probably
because<SUP> </SUP>there is a high concentration of GDP in the
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding assays which reduces the binding of
the radioligand<SUP> </SUP>substantially. At the highest concentrations of GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S
used, there<SUP> </SUP>is more than a 100-fold excess of GDP, and therefore it is
not<SUP> </SUP>surprising that the levels of <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;subunits detected by Western
blotting<SUP> </SUP>are roughly 100-fold higher than detected in the
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding assays. Nevertheless, in the present
study, based<SUP> </SUP>on these different determinations, the levels of receptor
and<SUP> </SUP>G protein subunits were similar in the membranes expressing
G<SUB>o</SUB><SUP> </SUP>and G<SUB>i2</SUB>. The two preparations are,
therefore, comparable, and<SUP> </SUP>any differences between the preparations are
unlikely to be caused<SUP> </SUP>either by receptor or G protein<SUP> </SUP>numbers.
    
    </P>

    
    <P>Agonist binding in the membranes expressing receptor and G protein
(G<SUB>o</SUB>, G<SUB>i2</SUB>) could, for many agonists, be resolved
into contributions<SUP> </SUP>from sites of higher and lower affinity in similar
proportions<SUP> </SUP>in the two preparations. This shows that the expressed
D<SUB>2</SUB> receptor<SUP> </SUP>and G proteins are able to interact. For two of
the agonists (dopamine,<SUP> </SUP>NPA</A>), GTP abolished the higher affinity binding
site. The affinity<SUP> </SUP>seen in the presence of GTP was similar to both the
lower affinity<SUP> </SUP>site seen in the absence of GTP and the affinity for
these agonists<SUP> </SUP>seen in a preparation containing receptor alone. These
data follow<SUP> </SUP>the predicted behavior of a system that conforms to a
ternary<SUP> </SUP>complex model with an excess of receptor over G protein (<A HREF="#B40">40</A>,<SUP> </SUP><A HREF="#B41">41</A>). The data on the levels of receptor and G protein in the<SUP> </SUP>membranes
show, however, that there is an excess of G protein<SUP> </SUP>over receptor of
about 20-fold. Similar discrepancies between<SUP> </SUP>inferred and measured R/G
ratios have been noted in other systems.<SUP> </SUP>It has been proposed (<A HREF="#B37">37</A>, <A HREF="#B42">42</A>)
that receptors and G proteins<SUP> </SUP>may not interact freely and that there
may be microdomains with<SUP> </SUP>different amounts of receptor and G protein.
Alternatively, the<SUP> </SUP>ternary complex models are an oversimplification and
receptor<SUP> </SUP>and G protein may form oligomers with properties different
from<SUP> </SUP>the predictions of the models (<A HREF="#B43">43</A>).
    
    </P>

    
    <P>Two observations from the ligand binding studies suggest that there may
be a greater affinity of the D<SUB>2</SUB> receptor for G<SUB>o</SUB>
than<SUP> </SUP>for G<SUB>i2</SUB> when occupied by several agonists. First, the
affinity<SUP> </SUP>of the higher affinity site is higher in the preparation
containing<SUP> </SUP>G<SUB>o</SUB>, for <I>m</I>-tyramine and NPA</A>. This
affinity difference should reflect<SUP> </SUP>the affinity of R/G coupling, given
that the ground state affinity<SUP> </SUP>of the receptor is similar in the two
preparations. Also, (<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP<SUP> </SUP>is unable to stabilize the higher
affinity state in the preparation<SUP> </SUP>containing G<SUB>i2</SUB> but can do
so in the preparation containing G<SUB>o</SUB>.<SUP> </SUP>In agreement with
these findings, differences in agonist affinity<SUP> </SUP>for one receptor
coupled to different G proteins have been described<SUP> </SUP>by others (<A HREF="#B11">11</A>, <A HREF="#B44">44</A>,
<A HREF="#B45">45</A>).
    
    </P>

    
    <P>A range of agonists was used to stimulate [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S
binding in the two preparations to assess G protein activation. Maximal<SUP> </SUP>agonist effects (relative to dopamine) were greater in the preparation<SUP> </SUP>containing G<SUB>o</SUB>, and some agonists (<I>p</I>-tyramine,
(<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP) were<SUP> </SUP>unable to stimulate [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding
at all in the preparation containing G<SUB>i2</SUB>. The<SUP> </SUP>potencies of
agonists to stimulate [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding were also
generally greater in the preparation<SUP> </SUP>containing G<SUB>o</SUB>, with
the exception of bromocriptine. These data<SUP> </SUP>suggest that there is a more
productive interaction between the<SUP> </SUP>D<SUB>2</SUB> receptor and
G<SUB>o</SUB>. The affinity of the interaction between receptor<SUP> </SUP>and G
protein may contribute to this, as suggested above from<SUP> </SUP>the ligand
binding data. The pattern of agonist binding and potencies<SUP> </SUP>in
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding assays is very similar in the
preparation containing<SUP> </SUP>G<SUB>o</SUB> compared with that seen for the
D<SUB>2</SUB> receptor expressed in CHO</A><SUP> </SUP>cells (<A HREF="#B23">23-25</A>). The present
system is, therefore, behaving similarly<SUP> </SUP>to a system in which the
receptor couples exclusively with endogenous<SUP> </SUP>mammalian G<SUP> </SUP>proteins.
    
    </P>

    
    <P>To understand the differences between the two preparations in more
detail, the data were analyzed to provide the
<I>K<SUB>l</SUB></I>/EC<SUB>50</SUB> ratio<SUP> </SUP>(ratio of agonist
binding dissociation constant to agonist potency)<SUP> </SUP>(Table
<a href="#TV">V</a>). The
<I>K<SUB>l</SUB></I>/EC<SUB>50</SUB> ratio (or amplification
ratio (<A HREF="#B24">24</A>, <A HREF="#B25">25</A>,<SUP> </SUP><A HREF="#B46">46</A>)) indicates the extent to which agonist activation of
a response<SUP> </SUP>occurs at lower concentrations than agonist binding to the
receptor<SUP> </SUP>and so is a measure of receptor/G protein activation. The
<I>K<SUB>l</SUB></I>/EC<SUB>50</SUB><SUP> </SUP>ratio of the agonists is
greater in the preparation containing<SUP> </SUP>G<SUB>o</SUB> than in the
preparation containing G<SUB>i2</SUB>, providing a further<SUP> </SUP>indication
that there is a more productive interaction between<SUP> </SUP>the
D<SUB>2</SUB> receptor and G<SUB>o</SUB>.

<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF><NOBR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</NOBR><BR><NOBR><STRONG>View this table:</STRONG></NOBR>
<BR><NOBR><A HREF="/cgi/content/full/276/31/28667/TV">[in this window]</A></NOBR><BR>
<NOBR><A HREF="/cgi/content-nw/full/276/31/28667/TV"
	onClick="startTarget('TV', 500, 400); this.href='/cgi/content-nw/full/276/31/28667/TV'"
	onMouseOver="window.status='View table in a separate window';
		return true"
TARGET='TV'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="TV"><!-- TABLE V --></A>
<CENTER>
<B>Table V</B><BR>
<STRONG>

    Agonist signaling parameters

<BR>
</STRONG>
</CENTER>
Parameters were derived from data in Tables <a href="#TIII">III</a> and <a href="#TIV">IV</a>.
<I>K</I><SUB><I>h</I></SUB> and <I>K</I><SUB><I>l</I></SUB> are respectively the
dissociation constants for the higher and lower affinity agonist
binding sites as in Table <a href="#TIII">III</a>. EC<SUB>50</SUB> is the concentration of
agonist which gives a 50% maximal response in the
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding assays as in Table <a href="#TIV">IV</a>.

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>



    
    </P>

    
    <P>For the preparation containing G<SUB>o</SUB>, greater
<I>K<SUB>l</SUB></I>/EC<SUB>50</SUB> ratios are generally
observed for the agonists that give greater maximal<SUP> </SUP>effects for
stimulation of [<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding. In this preparation,
therefore, the two measures<SUP> </SUP>of efficacy, agonist maximal effect and
<I>K<SUB>l</SUB></I>/EC<SUB>50</SUB>, are in agreement<SUP> </SUP>for a
range of compounds. For the preparation containing G<SUB>i2</SUB>,<SUP> </SUP>lower values of <I>K<SUB>l</SUB></I>/EC<SUB>50</SUB> are seen for
several agonists, but for<SUP> </SUP>two of the agonists, <I>p</I>-tyramine
and (<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP, no agonism is seen<SUP> </SUP>at all. For these compounds, binding
to the receptor appears to<SUP> </SUP>be insufficient to stabilize receptor/G
protein interaction. In<SUP> </SUP>this preparation, therefore, receptor/G protein
interaction is<SUP> </SUP>less efficient, and for some agonists there is a
complete failure<SUP> </SUP>to signal. The data outlined earlier show that the
affinity of<SUP> </SUP>the D<SUB>2</SUB> dopamine receptor is greater for
G<SUB>o</SUB> than for G<SUB>i2</SUB>. This<SUP> </SUP>cannot be the only factor
influencing the activation of the G<SUP> </SUP>proteins because otherwise a
general reduction in signaling efficiency<SUP> </SUP>would be seen for all
agonists tested when the lower affinity<SUP> </SUP>interaction is present,
<I>i.e.</I> in the G<SUB>i2</SUB> preparation. This suggests<SUP> </SUP>that
different agonists are able to stabilize different conformations<SUP> </SUP>of the
receptor with different affinities for the G protein and<SUP> </SUP>different
functional activities in the ternary complex rather<SUP> </SUP>than there being
differential stabilization of the same activated<SUP> </SUP>state by different
agonists. As a result, the selectivity of the<SUP> </SUP>D<SUB>2</SUB> receptor
for G<SUB>o</SUB> over G<SUB>i2</SUB> is dependent on the agonist
used.<SUP> </SUP>The two agonists that show the greatest selectivity,
<I>p</I>-tyramine<SUP> </SUP>and (<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BOTTOM ALT="-">)-3-PPP, are both monohydroxylated
compounds. It is interesting<SUP> </SUP>that for the <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>2A</SUB>-adrenergic
receptor, catechol agonists, <I>e.g.</I><SUP> </SUP>noradrenaline, lead to
stimulation of both G<SUB>i</SUB>- and
G<SUB>s</SUB>-dependent<SUP> </SUP>pathways, whereas monohydroxylated
agonists,  <I>e.g.</I> octopamine,<SUP> </SUP>lead only to activation of
G<SUB>i</SUB>-dependent pathways (<A HREF="#B47">47</A>).
    
    </P>

    
    <P>Further evidence that agonists may regulate the activity of the ternary
complex comes from analysis of the
<I>K<SUB>l</SUB></I>/<I>K<SUB>h</SUB></I> ratio (ratio<SUP> </SUP>of low
affinity and high affinity agonist dissociation constants).<SUP> </SUP>The
<I>K<SUB>l</SUB></I>/<I>K<SUB>h</SUB></I> ratio was derived
from the ligand binding data (Table<SUP> </SUP><a href="#TV">V</a>) because this has been proposed
to be an index of the ability<SUP> </SUP>of the agonist to stabilize receptor/G
protein coupling (see,<SUP> </SUP><I>e.g.</I> Ref. <A HREF="#B40">40</A>). There is no clear
relationship between the maximal<SUP> </SUP>effects of the agonists in
[<SUP>35</SUP>S]GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S binding assays and the
<I>K<SUB>l</SUB></I>/<I>K<SUB>h</SUB></I> ratio. Therefore,
stabilization<SUP> </SUP>of receptor/G protein coupling is not a clear predictor
of agonist<SUP> </SUP>efficacy, and similar results were seen in other studies on
the<SUP> </SUP>D<SUB>2</SUB> receptor expressed in CHO</A> cells (<A HREF="#B24">24</A>, <A HREF="#B25">25</A>). Agonists
may,<SUP> </SUP>therefore, influence the activity of the ternary complex as well<SUP> </SUP>as its formation (<A HREF="#B7">7</A>, <A HREF="#B8">8</A>, <A HREF="#B24">24</A>, <A HREF="#B25">25</A>).
    
    </P>

    
    <P>The behavior of bromocriptine provides further support for the idea
that agonists stabilize different receptor conformations.<SUP> </SUP>Bromocriptine
is a full agonist on both preparations, and its<SUP> </SUP>potency
(EC<SUB>50</SUB>) and binding affinity (<I>K<SUB>l</SUB></I>) are
similar in each preparation,<SUP> </SUP>leading to identical
<I>K<SUB>l</SUB></I>/EC<SUB>50</SUB> ratios, in contrast to the
other<SUP> </SUP>agonists tested. This suggests that the bromocriptine-receptor<SUP> </SUP>complex has a similar affinity for the two G proteins. Bromocriptine<SUP> </SUP>is
an unusual compound in that its binding to D<SUB>2</SUB> receptors
conforms<SUP> </SUP>to a single-site binding model (Table <a href="#TII">II</a>) and is insensitive
to<SUP> </SUP>guanine nucleotides (<A HREF="#B24">24</A>, <A HREF="#B25">25</A>, <A HREF="#B48">48</A>). It has been suggested<SUP> </SUP>that this is
because bromocriptine is able to stabilize a conformation<SUP> </SUP>of the
receptor which is close to the conformation in the active<SUP> </SUP>receptor-G
protein complex (<A HREF="#B49">49</A>, <A HREF="#B50">50</A>) so that there is little<SUP> </SUP>energy gain in
coupling to the G protein. This would be consistent<SUP> </SUP>with the present
findings in that the bromocriptine-receptor complex<SUP> </SUP>does not show any
discrimination between G<SUB>o</SUB> and G<SUB>i2</SUB>, and the G<SUP> </SUP>protein is fully active in each case. The close agreement between<SUP> </SUP><I>K<SUB>l</SUB></I> and EC<SUB>50</SUB> supports this<SUP> </SUP>contention.
    
    </P>

    
    <P>In conclusion, we have shown that the D<SUB>2</SUB> dopamine receptor
has a greater affinity for the G protein G<SUB>o</SUB> than for
G<SUB>i2</SUB>. Activation<SUP> </SUP>of G<SUB>o</SUB> occurs with higher
potencies for agonists and greater relative<SUP> </SUP>efficacies for partial
agonists, and this is in agreement with<SUP> </SUP>the findings of Yang and Lanier
(<A HREF="#B11">11</A>) for the <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>2</SUB>-adrenergic receptor.<SUP> </SUP>The data do not
provide evidence for agonist trafficking in that<SUP> </SUP>there are no clear
reversals of agonist potency. The pattern of<SUP> </SUP>agonist potencies is,
however, different for the two receptor-G<SUP> </SUP>protein combinations.
Therefore, the extent of selectivity of<SUP> </SUP>the D<SUB>2</SUB> dopamine
receptor for the two G proteins (G<SUB>o</SUB>, G<SUB>i2</SUB>)
depends<SUP> </SUP>on the agonist used. Different agonists, therefore, stabilize<SUP> </SUP>different conformations of the receptor which can couple to and<SUP> </SUP>activate G proteins<SUP> </SUP>differentially.
    
    


<BR><BR CLEAR=ALL>

</TXT>



<!-- Stray figures and tables -->


<!-- Acknowledgements -->

<!-- Notes -->


<!-- Footnotes -->

<A NAME="foo"><!-- comment for mosaic --></A>

<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;FOOTNOTES</FONT></TH>
</TR>
</TABLE>



<P><A NAME="FN150"><SUP>*</SUP></A>
This work was supported by a BBSRC studentship (to Y.&nbsp;C.)
and National Science Foundation Grant MCB-9870839 (to S.&nbsp;G.&nbsp;G.).The<SUP> </SUP>costs of publication of this
article were defrayed in part by<SUP> </SUP>the
payment of page charges. The article
must therefore be hereby<SUP> </SUP>marked
"<I>advertisement</I>" in
accordance with 18&nbsp;U.S.C. Section
1734<SUP>&nbsp;</SUP>solely to indicate this<SUP> </SUP>fact.

<P>
<P><A NAME="FN152"><SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP></A>
Present address: School of Biomedical Sciences, Queens Medical
Centre, Nottingham, NG7&nbsp;2UH,<SUP> </SUP>UK.

<P>
<P><A NAME="FN154"><SUP>&#182;</SUP></A>
To whom correspondence should be addressed. Tel.:
44-118-931-8015; Fax: 44-118-931-6537; E-mail:
P.G.Strange@rdg.ac.uk.

<P>


<P>
Published, JBC Papers in Press, May 21,&nbsp;2001,&nbsp;DOI 10.1074/jbc.M008644200

<P>

<A NAME="abb"><!-- comment for mosaic --></A>

<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;ABBREVIATIONS</FONT></TH>
</TR>
</TABLE>

<P>The abbreviations used are: 

R*, receptor in
partially activated state;

R*G, binary complex of G protein coupled to
activated receptor;

AR*G, ternary complex of agonist and R*G;

GTP<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BOTTOM ALT="gamma ">S, guanosine 5'-3-<I>O</I>- (thio)triphosphate;

CHO, Chinese hamster
ovary;

NMDG, <I>N</I>-methyl <font size=-1>D</font>-glucamine;

NPA, <I>N</I>-propyl norapomorphine;

<I>K<SUB>l</SUB></I>, low
affinity agonist dissociation constant;

<I>K<SUB>h</SUB></I>, high
affinity agonist dissociation constant;

3-PPP, 3-(3-hydroxyphenyl)-<I>N</I>-propylpiperidine.

</P>


<!-- Appendices -->

<!-- Bibliography -->




<A NAME="References"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;REFERENCES</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">INTRODUCTION</A>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">RESULTS</A>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">DISCUSSION</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>REFERENCES</FONT>
</FONT></TH>
</TR></TABLE>

<BR CLEAR=ALL>
<TABLE BORDER=0>
<TR><TD VALIGN=TOP><a name="B1">1.</a>
    <TD VALIGN=TOP>

Clarke, W. P.,
 and Bond, R. A.



(1998)

<I>Trends Pharmacol. Sci.</I>
<B>19</B>,
270-276<!-- HIGHWIRE ID="276:31:28667:1" --><A HREF="/cgi/external_ref?access_num=10.1016/S0165-6147(97)01138-3&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9703760&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9703760&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B2">2.</a>
    <TD VALIGN=TOP>

Gether, U.,
 and Kobilka, B. K.



(1998)

<I>J. Biol. Chem.</I>
<B>273</B>,
17979-17982<!-- HIGHWIRE ID="276:31:28667:2" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=jbc&resid=273/29/17979" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B3">3.</a>
    <TD VALIGN=TOP>

Kenakin, T. P.



(1993)


<I>Pharmacological Analysis of Drug-receptor Interactions</I>

, Raven Press, New York
    <!-- HIGHWIRE ID="276:31:28667:3" --><!-- /HIGHWIRE --></TR>
<TR><TD VALIGN=TOP><a name="B4">4.</a>
    <TD VALIGN=TOP>

De Lean, A.,
Stadel, J. M.,
 and Lefkowitz, R. J.



(1980)

<I>J. Biol. Chem.</I>
<B>255</B>,
7108-7117<!-- HIGHWIRE ID="276:31:28667:4" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=255/15/7108" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B5">5.</a>
    <TD VALIGN=TOP>

Samama, P.,
Cotecchia, S.,
Costa, T.,
 and Lefkowitz, R. J.



(1993)

<I>J. Biol. Chem.</I>
<B>268</B>,
4625-4636<!-- HIGHWIRE ID="276:31:28667:5" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=268/7/4625" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B6">6.</a>
    <TD VALIGN=TOP>

Weiss, J. M.,
Morhan, P. H.,
Lutz, M. W.,
 and Kenakin, T. P.



(1996)

<I>J. Theor. Biol.</I>
<B>178</B>,
151-167<!-- HIGHWIRE ID="276:31:28667:6" --><A HREF="/cgi/external_ref?access_num=10.1006/jtbi.1996.0014&link_type=DOI" >[CrossRef]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B7">7.</a>
    <TD VALIGN=TOP>

Hausdorff, W. P.,
Hnatowitch, M.,
O'Dowd, B. F.,
Caron, M. G.,
 and Lefkowitz, R. J.



(1990)

<I>J. Biol. Chem.</I>
<B>265</B>,
1388-1393<!-- HIGHWIRE ID="276:31:28667:7" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=265/3/1388" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B8">8.</a>
    <TD VALIGN=TOP>

Birnbaumer, L.,
Abramowitz, J.,
 and Brown, A. M.



(1990)

<I>Biochim. Biophys. Acta</I>
<B>1031</B>,
163-224<!-- HIGHWIRE ID="276:31:28667:8" --><A HREF="/cgi/external_ref?access_num=2160274&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=2160274&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B9">9.</a>
    <TD VALIGN=TOP>

Raymond, J. R.



(1999)

<I>Br. J.&nbsp;Pharmacol.</I>
<B>127</B>,
1751-1764<!-- HIGHWIRE ID="276:31:28667:9" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=brjpharmacol&resid=127/8/1751" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B10">10.</a>
    <TD VALIGN=TOP>

Gettys, T. W.,
Fields, T. A.,
 and Raymond, J. R.



(1994)

<I>Biochemistry</I>
<B>33</B>,
4283-4290<!-- HIGHWIRE ID="276:31:28667:10" --><A HREF="/cgi/external_ref?access_num=8155646&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=8155646&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B11">11.</a>
    <TD VALIGN=TOP>

Yang, Q.,
 and Lanier, S. M.



(1999)

<I>Mol. Pharmacol.</I>
<B>56</B>,
651-656<!-- HIGHWIRE ID="276:31:28667:11" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=56/3/651" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B12">12.</a>
    <TD VALIGN=TOP>

Kenakin, T.



(1995)

<I>Trends Pharmacol. Sci.</I>
<B>16</B>,
232-238<!-- HIGHWIRE ID="276:31:28667:12" --><A HREF="/cgi/external_ref?access_num=10.1016/S0165-6147(00)89032-X&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=7667897&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=7667897&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B13">13.</a>
    <TD VALIGN=TOP>




Neve, K., and Neve, R. A.
 (eds)

(1997)


<I>The Dopamine Receptors</I>

, Humana Press, Totowa, NJ
    <!-- HIGHWIRE ID="276:31:28667:13" --><!-- /HIGHWIRE --></TR>
<TR><TD VALIGN=TOP><a name="B14">14.</a>
    <TD VALIGN=TOP>

Ghahremani, M. H.,
Cheng, P.,
Lembo, P. M.&nbsp;C.,
 and Albert, P. R.



(1999)

<I>J. Biol. Chem.</I>
<B>274</B>,
9238-9245<!-- HIGHWIRE ID="276:31:28667:14" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=274/14/9238" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B15">15.</a>
    <TD VALIGN=TOP>

Liu, Y. F.,
Jakobs, K. H.,
Rasenick, M. M.,
 and Albert, P. R.



(1994)

<I>J. Biol. Chem.</I>
<B>269</B>,
13880-13886<!-- HIGHWIRE ID="276:31:28667:15" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=269/19/13880" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B16">16.</a>
    <TD VALIGN=TOP>

Meller, E.,
Puza, T.,
Diamond, J.,
Lieu, H. D.,
 and Bohmaker, K.



(1992)

<I>J. Pharmacol. Exp. Ther.</I>
<B>263</B>,
462-469<!-- HIGHWIRE ID="276:31:28667:16" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=263/2/462" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B17">17.</a>
    <TD VALIGN=TOP>

Summers, M. D.,
 and Smith, G. E.



(1987)

<I>Tex. Agric. Exp. Stn. Bull.</I>
<B>1555</B>,
5-53<!-- HIGHWIRE ID="276:31:28667:17" --><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B18">18.</a>
    <TD VALIGN=TOP>

Castro, S. W.,
 and Strange, P. G.



(1993)

<I>FEBS Lett.</I>
<B>315</B>,
223-226<!-- HIGHWIRE ID="276:31:28667:18" --><A HREF="/cgi/external_ref?access_num=10.1016/0014-5793(93)81168-Y&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=8422910&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=8422910&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B19">19.</a>
    <TD VALIGN=TOP>

Castro, S. W.,
 and Strange, P. G.



(1993)

<I>J. Neurochem.</I>
<B>60</B>,
372-375<!-- HIGHWIRE ID="276:31:28667:19" --><A HREF="/cgi/external_ref?access_num=8417160&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=8417160&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B20">20.</a>
    <TD VALIGN=TOP>

Sanderson, E. M.,
 and Strange, P. G.



(1995)

<I>Br. J.&nbsp;Pharmacol.</I>
<B>115</B>,
102<!-- HIGHWIRE ID="276:31:28667:20" --><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B21">21.</a>
    <TD VALIGN=TOP>

Graber, S. G.,
Figler, R. A.,
 and Garrison, J. C.



(1992)

<I>J. Biol. Chem.</I>
<B>267</B>,
1271-1278<!-- HIGHWIRE ID="276:31:28667:21" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=267/2/1271" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B22">22.</a>
    <TD VALIGN=TOP>

Lowry, O. H.,
Rosebrough, N. J.,
Farr, A. L.,
 and Randall, R. J.



(1951)

<I>J. Biol. Chem.</I>
<B>193</B>,
265-275<!-- HIGHWIRE ID="276:31:28667:22" --><A HREF="/cgi/ijlink?linkType=PDF&journalCode=jbc&resid=193/1/265" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B23">23.</a>
    <TD VALIGN=TOP>

Gardner, B.,
Hall, D. A.,
 and Strange, P. G.



(1996)

<I>Br. J.&nbsp;Pharmacol.</I>
<B>118</B>,
1544-1550<!-- HIGHWIRE ID="276:31:28667:23" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=brjpharmacol&resid=118/6/1544" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B24">24.</a>
    <TD VALIGN=TOP>

Gardner, B.,
Hall, D. A.,
 and Strange, P. G.



(1997)

<I>J. Neurochem.</I>
<B>69</B>,
2589-2598<!-- HIGHWIRE ID="276:31:28667:24" --><A HREF="/cgi/external_ref?access_num=9375693&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9375693&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B25">25.</a>
    <TD VALIGN=TOP>

Gardner, B.,
 and Strange, P. G.



(1998)

<I>Br. J.&nbsp;Pharmacol.</I>
<B>124</B>,
978-984<!-- HIGHWIRE ID="276:31:28667:25" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=brjpharmacol&resid=124/5/978" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B26">26.</a>
    <TD VALIGN=TOP>

Strange, P. G.



(1996)

<I>Neuropsychopharmacology</I>
<B>16</B>,
116-122<!-- HIGHWIRE ID="276:31:28667:26" --><A HREF="/cgi/external_ref?access_num=10.1016/S0893-133X(96)00191-1&link_type=DOI" >[CrossRef]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B27">27.</a>
    <TD VALIGN=TOP>

Wenzel-Seifert, K.,
Hurt, C. M.,
 and Seifert, R



(1998)

<I>J. Biol. Chem.</I>
<B>273</B>,
24181-24189<!-- HIGHWIRE ID="276:31:28667:27" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=273/37/24181" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B28">28.</a>
    <TD VALIGN=TOP>

Barr, A. J.,
 and Manning, D. R.



(1997)

<I>J. Biol. Chem.</I>
<B>272</B>,
32979-32987<!-- HIGHWIRE ID="276:31:28667:28" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=272/52/32979" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B29">29.</a>
    <TD VALIGN=TOP>

Boundy, V. A.,
Lu, L.,
 and Molinoff, P. B.



(1996)

<I>J. Pharmacol. Exp. Ther.</I>
<B>276</B>,
784-794<!-- HIGHWIRE ID="276:31:28667:29" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=276/2/784" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B30">30.</a>
    <TD VALIGN=TOP>

Figler, R. A.,
Graber, S. G.,
Lindorfer, M. A.,
Yasuda, H.,
Linden, J.,
 and Garrison, J. C.



(1996)

<I>Mol. Pharmacol.</I>
<B>50</B>,
1587-1595<!-- HIGHWIRE ID="276:31:28667:30" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=50/6/1587" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B31">31.</a>
    <TD VALIGN=TOP>

Grunewald, S.,
Reilander, H.,
 and Michel, H.



(1996)

<I>Biochemistry</I>
<B>35</B>,
15162-15173<!-- HIGHWIRE ID="276:31:28667:31" --><A HREF="/cgi/external_ref?access_num=10.1021/bi960757w&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=8952463&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=8952463&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B32">32.</a>
    <TD VALIGN=TOP>

Wenzel-Seifert, K.,
 and Seifert, R.



(2000)

<I>Mol. Pharmacol.</I>
<B>58</B>,
954-966<!-- HIGHWIRE ID="276:31:28667:32" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=58/5/954" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B33">33.</a>
    <TD VALIGN=TOP>

McCallum, J. F.,
Wise, A.,
Grassie, M. A.,
Magee, A. I.,
Guzzi, F.,
Parenti, M.,
 and Milligan, G.



(1995)

<I>Biochem. J.</I>
<B>310</B>,
1021-1027<!-- HIGHWIRE ID="276:31:28667:33" --><A HREF="/cgi/external_ref?access_num=7575398&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=7575398&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B34">34.</a>
    <TD VALIGN=TOP>

Ransnas, L. A.,
Jasper, J. R.,
Leiber, D.,
 and Insel, P. A.



(1992)

<I>Biochem. J.</I>
<B>283</B>,
519-524<!-- HIGHWIRE ID="276:31:28667:34" --><A HREF="/cgi/external_ref?access_num=1315517&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=1315517&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B35">35.</a>
    <TD VALIGN=TOP>

Svoboda, P.,
Kim, G. D.,
Grassie, M. A.,
Eidne, K. A.,
 and Milligan, G.



(1996)

<I>Mol. Pharmacol.</I>
<B>49</B>,
646-655<!-- HIGHWIRE ID="276:31:28667:35" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=49/4/646" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B36">36.</a>
    <TD VALIGN=TOP>

Edgerton, M. D.,
Chabert, C.,
Chollet, A.,
 and Arkinstall, S.



(1994)

<I>FEBS Lett.</I>
<B>354</B>,
195-199<!-- HIGHWIRE ID="276:31:28667:36" --><A HREF="/cgi/external_ref?access_num=10.1016/0014-5793(94)01101-X&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=7957923&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=7957923&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B37">37.</a>
    <TD VALIGN=TOP>

Neubig, R. R.



(1994)

<I>FASEB J.</I>
<B>8</B>,
939-946<!-- HIGHWIRE ID="276:31:28667:37" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=fasebj&resid=8/12/939" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B38">38.</a>
    <TD VALIGN=TOP>

Ransnas, L. A.,
 and Insel, P. A.



(1988)

<I>J. Biol. Chem.</I>
<B>263</B>,
9482-9485<!-- HIGHWIRE ID="276:31:28667:38" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=263/19/9482" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B39">39.</a>
    <TD VALIGN=TOP>

Selley, D. E.,
Sim, L. J.,
Xiao, R.,
Liu, Q.,
 and Childers, S. R.



(1997)

<I>Mol. Pharmacol.</I>
<B>51</B>,
87-96<!-- HIGHWIRE ID="276:31:28667:39" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=51/1/87" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B40">40.</a>
    <TD VALIGN=TOP>

Wreggett, K. A.,
 and DeLean, A.



(1984)

<I>Mol. Pharmacol.</I>
<B>26</B>,
214-227<!-- HIGHWIRE ID="276:31:28667:40" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=26/2/214" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B41">41.</a>
    <TD VALIGN=TOP>

Lee, T. W.&nbsp;T.,
Sole, M. J.,
 and Wells, J. W.



(1986)

<I>Biochemistry</I>
<B>25</B>,
7009-7020<!-- HIGHWIRE ID="276:31:28667:41" --><A HREF="/cgi/external_ref?access_num=2879554&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=2879554&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B42">42.</a>
    <TD VALIGN=TOP>

Jakubik, J.,
Haga, T.,
 and Tucek, S.



(1998)

<I>Mol. Pharmacol.</I>
<B>54</B>,
899-906<!-- HIGHWIRE ID="276:31:28667:42" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=54/5/899" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B43">43.</a>
    <TD VALIGN=TOP>

Chidiac, P.



(1998)

<I>Biochem. Pharmacol.</I>
<B>55</B>,
549-556<!-- HIGHWIRE ID="276:31:28667:43" --><A HREF="/cgi/external_ref?access_num=10.1016/S0006-2952(97)00361-4&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9515565&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9515565&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B44">44.</a>
    <TD VALIGN=TOP>

Bae, H.,
Anderson, K.,
Flood, L. A.,
Skiba, N. P.,
Hamm, H. E.,
 and Graber, S. G.



(1997)

<I>J. Biol. Chem.</I>
<B>272</B>,
32071-32077<!-- HIGHWIRE ID="276:31:28667:44" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=272/51/32071" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B45">45.</a>
    <TD VALIGN=TOP>

Clawges, H. M.,
Depree, K. M.,
Parker, E. M.,
 and Graber, S. G.



(1997)

<I>Biochemistry</I>
<B>36</B>,
12930-12938<!-- HIGHWIRE ID="276:31:28667:45" --><A HREF="/cgi/external_ref?access_num=10.1021/bi970112b&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9335552&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9335552&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B46">46.</a>
    <TD VALIGN=TOP>

Black, J. W.,
 and Leff, P.



(1983)

<I>Proc. R.&nbsp;Soc. Lond. B Biol. Sci.</I>
<B>220</B>,
141-162<!-- HIGHWIRE ID="276:31:28667:46" --><A HREF="/cgi/external_ref?access_num=6141562&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=6141562&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B47">47.</a>
    <TD VALIGN=TOP>

Airriess, C. N.,
Rudling, J. E.,
Midgely, J. M.,
 and Evans, P. D.



(1997)

<I>Br. J.&nbsp;Pharmacol.</I>
<B>122</B>,
191-198<!-- HIGHWIRE ID="276:31:28667:47" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=brjpharmacol&resid=122/2/191" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B48">48.</a>
    <TD VALIGN=TOP>

Sibley, D.,
 and Creese, I.



(1983)

<I>Mol. Pharmacol.</I>
<B>23</B>,
585-593<!-- HIGHWIRE ID="276:31:28667:48" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=23/3/585" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B49">49.</a>
    <TD VALIGN=TOP>

Strange, P. G.



(1998)

<I>Trends Pharmacol. Sci.</I>
<B>19</B>,
85-86<!-- HIGHWIRE ID="276:31:28667:49" --><A HREF="/cgi/external_ref?access_num=10.1016/S0165-6147(98)01175-4&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9584623&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9584623&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B50">50.</a>
    <TD VALIGN=TOP>

Strange, P. G.



(1999)

<I>Biochem. Pharmacol.</I>
<B>58</B>,
1081-1088<!-- HIGHWIRE ID="276:31:28667:50" --><A HREF="/cgi/external_ref?access_num=10.1016/S0006-2952(99)00144-6&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10484065&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10484065&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>

</TABLE>



<P><HR>
<FONT SIZE=-1><A HREF="/misc/terms.shtml"><B>Copyright &#169; 2001 by The American Society for Biochemistry and Molecular Biology, Inc.</B></A></FONT>




<!--

   Pages created by the Electronic Press Engine from

		Atypon Systems, Inc.

   Visit http://www.atypon.com/

-->


</vardef>

		
        
        
	
	
	
	



 




<BR CLEAR=ALL>



  <FONT FACE="">
  
  </FONT>
<BR CLEAR=ALL>
<BR CLEAR=ALL>



<A NAME="otherarticles"><!-- null --></A>
<P>
<FONT SIZE=+2><STRONG>This article has been cited by other articles:</STRONG></FONT>
<P>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.brjpharmacol.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.brjpharmacol.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.brjpharmacol.org"><IMG ALT="Br. J. Pharmacol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/brjpharmacol.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Y. Cordeaux, A. P IJzerman, and S. J Hill<BR>
	<STRONG>Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation</STRONG><BR>
	
		
			Br. J. Pharmacol.,
		
	
        
        November&nbsp;6,&nbsp;2004;
	143(6):
	705 - 714.
<BR>
<A HREF="http://www.brjpharmacol.org/cgi/content/abstract/143/6/705">[Abstract]</A>

<A HREF="http://www.brjpharmacol.org/cgi/content/full/143/6/705">[Full Text]</A>
<A HREF="http://www.brjpharmacol.org/cgi/reprint/143/6/705">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. J. Millan, D. Cussac, A. Gobert, F. Lejeune, J.-M. Rivet, C. M. La Cour, A. Newman-Tancredi, and J.-L. Peglion<BR>
	<STRONG>S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        June&nbsp;1,&nbsp;2004;
	309(3):
	903 - 920.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/309/3/903">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/309/3/903">[Full Text]</A>
<A HREF="http://www.jpet.org/cgi/reprint/309/3/903">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://edrv.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://edrv.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://edrv.endojournals.org"><IMG ALT="Endocr Rev" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/edrv.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	R. P. Millar, Z.-L. Lu, A. J. Pawson, C. A. Flanagan, K. Morgan, and S. R. Maudsley<BR>
	<STRONG>Gonadotropin-Releasing Hormone Receptors</STRONG><BR>
	
		
			Endocr. Rev.,
		
	
        
        April&nbsp;1,&nbsp;2004;
	25(2):
	235 - 275.
<BR>
<A HREF="http://edrv.endojournals.org/cgi/content/abstract/25/2/235">[Abstract]</A>

<A HREF="http://edrv.endojournals.org/cgi/content/full/25/2/235">[Full Text]</A>
<A HREF="http://edrv.endojournals.org/cgi/reprint/25/2/235">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	V. D. Nair and S. C. Sealfon<BR>
	<STRONG>Agonist-specific Transactivation of Phosphoinositide 3-Kinase Signaling Pathway Mediated by the Dopamine D2 Receptor</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        November&nbsp;21,&nbsp;2003;
	278(47):
	47053 - 47061.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/278/47/47053">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/278/47/47053">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/278/47/47053">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J. Gonzalez-Maeso, T. Yuen, B. J. Ebersole, E. Wurmbach, A. Lira, M. Zhou, N. Weisstaub, R. Hen, J. A. Gingrich, and S. C. Sealfon<BR>
	<STRONG>Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        October&nbsp;1,&nbsp;2003;
	23(26):
	8836 - 8843.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/23/26/8836">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/23/26/8836">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/23/26/8836">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://content.febsjournal.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://content.febsjournal.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://content.febsjournal.org"><IMG ALT="FEBS J" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ejbiochem.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	L. Gazi, J. F. Lopez-Gimenez, M. P. Rudiger, and P. G. Strange<BR>
	<STRONG>Constitutive oligomerization of human D2 dopamine receptors expressed in Spodoptera frugiperda 9 (Sf9 ) and in HEK293 cells: Analysis using co-immunoprecipitation and time-resolved fluorescence resonance energy transfer</STRONG><BR>
	
		
			FEBS J.,
		
	
        
        October&nbsp;1,&nbsp;2003;
	270(19):
	3928 - 3938.
<BR>
<A HREF="http://www.ejbiochem.org/cgi/content/abstract/270/19/3928">[Abstract]</A>

<A HREF="http://www.ejbiochem.org/cgi/content/full/270/19/3928">[Full Text]</A>
<A HREF="http://www.ejbiochem.org/cgi/reprint/270/19/3928">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	K. Masuda, H. Itoh, T. Sakihama, C. Akiyama, K. Takahashi, R. Fukuda, T. Yokomizo, T. Shimizu, T. Kodama, and T. Hamakubo<BR>
	<STRONG>A Combinatorial G Protein-coupled Receptor Reconstitution System on Budded Baculovirus: EVIDENCE FOR G{alpha}i AND  G{alpha}o COUPLING TO A HUMAN LEUKOTRIENE B4  RECEPTOR</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        July&nbsp;4,&nbsp;2003;
	278(27):
	24552 - 24562.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/278/27/24552">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/278/27/24552">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/278/27/24552">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.brjpharmacol.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.brjpharmacol.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.brjpharmacol.org"><IMG ALT="Br. J. Pharmacol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/brjpharmacol.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	L. Gazi, S. A. Nickolls, and P. G. Strange<BR>
	<STRONG>Functional coupling of the human dopamine D2 receptor with G{alpha}i1, G{alpha}i2, G{alpha}i3 and G{alpha}o G proteins: evidence for agonist regulation of G protein selectivity</STRONG><BR>
	
		
			Br. J. Pharmacol.,
		
	
        
        March&nbsp;5,&nbsp;2003;
	138(5):
	775 - 786.
<BR>
<A HREF="http://www.brjpharmacol.org/cgi/content/abstract/138/5/775">[Abstract]</A>

<A HREF="http://www.brjpharmacol.org/cgi/content/full/138/5/775">[Full Text]</A>
<A HREF="http://www.brjpharmacol.org/cgi/reprint/138/5/775">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. A. Nickolls, M. I. Cismowski, X. Wang, M. Wolff, P. J. Conlon, and R. A. Maki<BR>
	<STRONG>Molecular Determinants of Melanocortin 4 Receptor Ligand Binding and MC4/MC3 Receptor Selectivity</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        March&nbsp;1,&nbsp;2003;
	304(3):
	1217 - 1227.
<BR>
<A HREF="http://jpet.aspetjournals.org/cgi/content/abstract/304/3/1217">[Abstract]</A>

<A HREF="http://jpet.aspetjournals.org/cgi/content/full/304/3/1217">[Full Text]</A>
<A HREF="http://jpet.aspetjournals.org/cgi/reprint/304/3/1217">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. Prioleau, I. Visiers, B. J. Ebersole, H. Weinstein, and S. C. Sealfon<BR>
	<STRONG>Conserved Helix 7 Tyrosine Acts as a Multistate Conformational Switch in the 5HT2C Receptor. IDENTIFICATION OF A NOVEL "LOCKED-ON" PHENOTYPE AND DOUBLE REVERTANT MUTATIONS</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        September&nbsp;27,&nbsp;2002;
	277(39):
	36577 - 36584.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/277/39/36577">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/277/39/36577">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/277/39/36577">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J. N. McLaughlin, C. D. Thulin, S. M. Bray, M. M. Martin, T. S. Elton, and B. M. Willardson<BR>
	<STRONG>Regulation of Angiotensin II-induced G Protein Signaling by Phosducin-like Protein</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        September&nbsp;20,&nbsp;2002;
	277(38):
	34885 - 34895.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/277/38/34885">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/277/38/34885">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/277/38/34885">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://mend.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://mend.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://mend.endojournals.org"><IMG ALT="Mol Endocrinol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/mend.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Y.-X. Tao, D. Mizrachi, and D. L. Segaloff<BR>
	<STRONG>Chimeras of the Rat and Human FSH Receptors (FSHRs) Identify Residues that Permit or Suppress Transmembrane 6 Mutation-Induced Constitutive Activation of the FSHR via Rearrangements of Hydrophobic Interactions Between Helices 6 and 7</STRONG><BR>
	
		
			Mol. Endocrinol.,
		
	
        
        August&nbsp;1,&nbsp;2002;
	16(8):
	1881 - 1892.
<BR>
<A HREF="http://mend.endojournals.org/cgi/content/abstract/16/8/1881">[Abstract]</A>

<A HREF="http://mend.endojournals.org/cgi/content/full/16/8/1881">[Full Text]</A>
<A HREF="http://mend.endojournals.org/cgi/reprint/16/8/1881">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	











<BR CLEAR=ALL>


	
	 
		
		  
			
	
		<table class="content_box_outer_table"
		 
			
				
					
						align="right"
					
				
			
		>
			<tr>
			<td>
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				
				<strong><a href="/cgi/content/abstract/276/31/28667">
				Abstract</a></strong>
				 					<img alt="" width="32" height="7" border="0" src="/icons/shared/toc/free.gif">
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	

	
	
	

	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		
		
		
			
				
				
					<a href="/cgi/reprint/276/31/28667">
		<strong>Full Text</strong> (PDF)</a>
				
			
		
		</strong>
		</td></tr>
	
	

	
	
	

	
	
	

	
	





	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			

			
	
	

	
		
	









	
		
	
		
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item"><strong>
			All Versions of this Article:<br>
		
			
					276/31/28667
				
		&nbsp;&nbsp;&nbsp;<font color="#006699"><em>most recent</em></font><br>
	

	
		
		
			<a href="/cgi/content/short/M008644200v1">
					M008644200v1</a>
			
		</strong></td></tr>
	

	





	

	 

	

	
	
		  
    

	







		
	
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=jbc;276/31/28667&return_type=article&return_url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F31%2F28667">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=correction&addAlert=correction&saveAlert=no&correction_criteria_value=276/31/28667&return_type=article&return_url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F31%2F28667">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		










			
		
			
			
			
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
					<strong><a href="/cgi/citemap?id=jbc;276/31/28667">
					Citation Map</a></strong>
				</td></tr>
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/mailafriend?url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F31%2F28667&title=Agonist+Regulation+of+D2+Dopamine+Receptor%2FG+Protein+Interaction.+EVIDENCE+FOR+AGONIST+SELECTION+OF+G+PROTEIN+SUBTYPE">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

		
		



			
			
			
		
	

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		<a href="/cgi/search?qbe=jbc;M008644200&journalcode=jbc&minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=11369753&link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
	

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="/cgi/citmgr?gca=jbc;276/31/28667">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	


	

	

		


	
	
	
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><A HREF="/misc/ASBMB_Copyright_Request.pdf">Copyright Permissions</a></strong>
			</td></tr>
		

	

	






	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=11369753&link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Cordeaux+Y&link_type=AUTHORSEARCH">
							Articles by Cordeaux, Y.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Strange+PG&link_type=AUTHORSEARCH">
							Articles by Strange, P. G.</a></strong>
						</td></tr>
				
			
		

		
	






	






	
		

	

		
			
		











	




	</td></tr></table>
</td></tr></table> 

					
					
	

<BR CLEAR=ALL>








	
	<P>
	<HR NOSHADE ALIGN="LEFT" WIDTH="450" SIZE="1">
	
	<TABLE CELLPADDING="2" CELLSPACING="2" WIDTH="450">
	<TR>
		<TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">HOME</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/help/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">HELP</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/cgi/feedback"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">FEEDBACK</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/subscriptions/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">SUBSCRIPTIONS</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/contents-by-date.0.shtml"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">ARCHIVE</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/search.dtl"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">SEARCH</FONT></A></TD>
	    


<TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/content/vol276/issue31/index.shtml"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">TABLE OF CONTENTS</FONT></A></TD>




	</TR>
	</TABLE>
	
	


	
<TABLE CELLPADDING="2" CELLSPACING="2" BORDER="0">
<TR>
	<TD BGCOLOR="#006699" ALIGN="CENTER" NOWRAP>&nbsp;<A STYLE="text-decoration:none" HREF="http://www.asbmb.org/"><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">All ASBMB Journals</A></STRONG>&nbsp;</TD>
	<TD BGCOLOR="#CC0000" ALIGN="CENTER" NOWRAP>&nbsp;<A STYLE="text-decoration:none" HREF="http://www.mcponline.org/"><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">Molecular and Cellular Proteomics</A></STRONG>&nbsp;</TD>
</TR><TR>
	<TD BGCOLOR="#0099FF" ALIGN="CENTER" NOWRAP>&nbsp;<A STYLE="text-decoration:none" HREF="http://www.jlr.org/"><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">Journal of Lipid Research</A></STRONG>&nbsp;</TD>
	<TD BGCOLOR="#003F77" ALIGN="CENTER" NOWRAP>&nbsp;<A STYLE="text-decoration:none" HREF="http://www.bambed.org/"><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">Biochemistry and Molecular Biology Education</A></STRONG>&nbsp;</TD>
</TR>
</TABLE>

	<FONT SIZE="-1"><STRONG><A TARGET="_top" HREF="/misc/terms.shtml">Copyright &copy; 2001 by the American Society for Biochemistry and Molecular Biology.</A></STRONG></FONT>
	


</BODY>
</HTML>
